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Abstract
Age-related macular degeneration (AMD), typically manifesting as a loss of central vision in elderly persons,
is a leading cause of blindness in highly developed nations. AMD is a multifactorial disease associated with
aging, oxidative stress, complement dysregulation, dsRNA toxicity, among many other possible factors. The
formation of extracellular deposits, termed drusen, below the retinal pigment epithelial (RPE) cell layer in the
outer retina is a pathognomonic hallmark of AMD. The composition of drusen is complex, but identified
elements include iron, complement components, and amyloid protein derivatives. This suggests that iron may
be involved in the pathophysiology of AMD. Further support for this hypothesis comes from mice lacking
ferroxidases Ceruloplasmin (Cp) and Hephaestin (Heph), which have a primary genetic defect in iron
homeostasis. These mice develop some AMD-like morphological features and a telling molecular feature:
activated complement component 3 (C3) fragment deposition at the basolateral aspect of the RPE (the
location of drusen in AMD). In our studies, we investigated the molecular mechanisms by which C3 is up-
regulated by iron in RPE cells. ERK1/2, SMAD3, and CCAAT/enhancer-binding protein-δ (C/EBP-δ) are
part of a non-canonical TGF-β signaling pathway that is responsible for iron-induced C3 expression.
Pharmacologic inhibition of either ERK1/2 or SMAD3 phosphorylation decreased iron-induced C3
expression levels. Knockdown of SMAD3 blocked the iron-induced up-regulation and nuclear accumulation
of C/EBP-δ, a transcription factor known to promote C3 expression by binding to the basic leucine zipper
(bZIP1) domain of the gene promoter. We show herein that mutation of this domain reduced iron-induced
C3 promoter activity. The molecular events in the iron-C3 pathway represent therapeutic targets for AMD. To
better understand the relative contribution of systemic iron and local dysregulation of iron homeostasis to
RPE iron accumulation, we used Bmp6 KO mice and WT mice and found that retinal hepcidin levels are not
changed, but in fact may be slightly greater in KO compared to WT mice. As such, systemic iron overload by
genetic KO or intravenous supplementation in WT mice resulted in increased RPE labile iron and oxidative
stress, suggesting that systemic iron overload may lead to retinal iron overload despite the presence of an intact
blood retinal barrier. Systemic iron status appears to be a leading determinant of retinal iron status.
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ABSTRACT 
IRON-INDUCED COMPLEMENT DYSREGULATION IN THE RETINAL PIGMENT EPITHELIUM: 
IMPLICATIONS FOR AGE-RELATED MACULAR DEGENERATION 
Yafeng Li 
Joshua L. Dunaief, MD PhD 
Age-related macular degeneration (AMD), typically manifesting as a loss of central vision in 
elderly persons, is a leading cause of blindness in highly developed nations.  AMD is a 
multifactorial disease associated with aging, oxidative stress, complement dysregulation, dsRNA 
toxicity, among many other possible factors.  The formation of extracellular deposits, termed 
drusen, below the retinal pigment epithelial (RPE) cell layer in the outer retina is a pathognomonic 
hallmark of AMD.  The composition of drusen is complex, but identified elements include iron, 
complement components, and amyloid protein derivatives.  This suggests that iron may be 
involved in the pathophysiology of AMD.  Further support for this hypothesis comes from mice 
lacking ferroxidases Ceruloplasmin (Cp) and Hephaestin (Heph), which have a primary genetic 
defect in iron homeostasis. These mice develop some AMD-like morphological features and a 
telling molecular feature: activated complement component 3 (C3) fragment deposition at the 
basolateral aspect of the RPE (the location of drusen in AMD).  In our studies, we investigated 
the molecular mechanisms by which C3 is up-regulated by iron in RPE cells.  ERK1/2, SMAD3, 
and CCAAT/enhancer-binding protein-δ (C/EBP-δ) are part of a non-canonical TGF-β signaling 
pathway that is responsible for iron-induced C3 expression.  Pharmacologic inhibition of either 
ERK1/2 or SMAD3 phosphorylation decreased iron-induced C3 expression levels.  Knockdown of 
SMAD3 blocked the iron-induced up-regulation and nuclear accumulation of C/EBP-δ, a 
transcription factor known to promote C3 expression by binding to the basic leucine zipper 
(bZIP1) domain of the gene promoter.  We show herein that mutation of this domain reduced iron-
induced C3 promoter activity.  The molecular events in the iron-C3 pathway represent therapeutic 
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targets for AMD.  To better understand the relative contribution of systemic iron and local 
dysregulation of iron homeostasis to RPE iron accumulation, we used Bmp6 KO mice and WT 
mice and found that retinal hepcidin levels are not changed, but in fact may be slightly greater in 
KO compared to WT mice.  As such, systemic iron overload by genetic KO or intravenous 
supplementation in WT mice resulted in increased RPE labile iron and oxidative stress, 
suggesting that systemic iron overload may lead to retinal iron overload despite the presence of 
an intact blood retinal barrier.  Systemic iron status appears to be a leading determinant of retinal 
iron status. 
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CHAPTER 1 
An overview of the mammalian retina 
The mammalian retina is a highly structured tissue, approximately 0.5mm in thickness, 
lining the back of eye.  This structure is shown schematically in Fig. 1.1.  Although the retina is 
anatomically and functionally complex, we generally consider the retina as having two general 
components: the neurosensory retina (NR), composed of neuronal and support cells, and the 
retinal pigment epithelium (RPE).   
The RPE, as the name suggests, is a pigmented monolayer of cells that makes contact 
with the photoreceptors to phagocytose their outer segments on a daily basis, regenerates the 
visual chromosphore 11-cis retinal, and maintains the blood-outer retina barrier while regulating 
epithelial transport, among its various critical functions.  
The NR has at least five types of neurons: photoreceptors, bipolar cells, ganglion cells, 
horizontal cells, and amacrine cells.  The support, or glial cells are the astrocytes and the Müller 
cells.  All of these cells can be located within the three layers of neuronal cell bodies and two 
layers of synapses that compose the NSR.   
The outer nuclear layer (ONL) contains the cell bodies of the rod and cone 
photoreceptors, which are sensitive to different wavelengths of lights.  In the photoreceptor outer 
segments, light energy in the form of photons are converted into graded electrochemical 
potentials.  The structures that allow this to occur within the photoreceptors are densely packed 
lipid-bilayer disc structures and photo-sensitive proteins, such as opsins and transducins.  The 
inner segments of the photoreceptors contain the cell nuclei and are rich in mitochondria.  The 
synaptic connections between rod/cones, vertically running bipolar cells, and laterally-oriented 
horizontal cells occur in the outer plexiform layer (OPL).   
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  Photons 
 
Figure 1.1 Schematic of the mammalian retina.  Proceeding from the top to bottom, we begin 
with the outermost layer (top), the retinal pigment epithelium (RPE, white with gray nuclei).  
Photoreceptors, as either rods (blue) or cones (red, green, aqua blue), have nuclei in the outer 
nuclear layer (ONL).  Between the RPE and the ONL lies the outer segments (OS) and inner 
segments (IS) of the photoreceptors.  The synaptic layer between the photoreceptors and the 
bipolar cells is called the outer plexiform layer (OPL).  The cell bodies of Müller glia (gray outline), 
bipolar cells (taupe), horizontal cells (yellow), and amacrine cells (orange) are located in the inner 
nuclear layer (INL). But horizontal cells synapse in the OPL and amacrine cells synapse in the 
IPL, the layer between bipolar cells and ganglion cells.  The ganglion cell layer (GCL) contains 
the cell bodies of ganglion cells (purple).  Müller glia span from the inner limiting membrane (ILM) 
adjacent to the vitreous to the outer limiting membrane (OLM), where photoreceptor cell OS takes 
form.  Figure adapted from http://webvision.med.utah.edu. 
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 The inner nuclear layer (INL) contains the cell bodies of the bipolar, horizontal, and 
amacrine cells.  The Müller glia cell bodies can also be found in the INL.  These unique cells 
project their processes all the way from the inner limiting membrane, near the ganglion cell layer 
(GCL), in one direction, all the way to the outer limiting membrane, at the outer edge of the ONL, 
in the opposite direction.  Generally, bipolar cells receive input from photoreceptors and relay the 
signals to ganglion cells.  The horizontal cells serve as interneurons that modulate the lateral 
transmission of signals at the synaptic interface of photoreceptor and bipolar cells.  Amacrine 
cells are a different type of interneuron, in that they modulate the lateral interactions of the 
synapses of bipolar and ganglion cells, otherwise known as the inner plexiform layer (IPL).   
The ganglion cell layer (GCL), the innermost retinal structure, contains the cell bodies of 
ganglion cells.  Ganglion cells receive the integrated signals from the neural processing networks 
in the IPL, and transmit, to the brain, information regarding the visual image as action potentials 
along its own axons, which constitute the optic nerve. 
 
Classification, epidemiology and pathogenesis of AMD 
 AMD is a degenerative disease of the central retina (macula) that results primarily in the 
loss of central vision in elderly persons.  Loss of central vision impairs most activities of daily 
living and presents a great health burden on the individuals affected and their families.  AMD is 
clinically classified into dry (atrophic) or wet (neovascular) types.  In dry AMD, clinical findings 
may include subretinal drusen deposits, focal or more widespread geographic atrophy of the 
RPE, and RPE detachments/clumping.  Drusen are localized deposits of extracellular material, 
usually found in the macular region, and appear as small, yellowish-white spots on 
ophthalmoscopy (Fig. 1.2).  In many individuals over the age of 50, a few small, hard drusen are 
detected as a normal consequence of aging (Jager et al., 2008).  On the other hand, larger, soft 
drusen are more strongly associated with disease progression and vision loss.  These larger, soft 
drusen, possibly accompanied by RPE clumping, increases the risk for developing the wet form of 
AMD (Jager et al., 2008).  Wet AMD is characterized by the abnormal growth of blood vessels  
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Figure 1.2 Funduscopic image of dry type age-related macular degeneration (AMD) with findings 
of pervasive, small, yellowish-white drusen and a region of atrophy in the macula.  Reproduced 
with permission from the Massachusetts Eye & Ear Infirmary, Photographer, David Walsh.  
Graphic 58340 Version 2.0; Accessed from Up-To-Date: Age-related macular degeneration. 
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from the choroidal circulation, and less frequently from the retinal circulation, into the subretinal 
space.  These leaky new vessels form pockets of subretinal fluid and/or blood, leading eventually 
to fibrous scarring.  Although the wet form of disease only accounts for 10 to 15% of AMD cases, 
it accounts for more than 80% of all AMD cases with severe vision loss or legal blindness (Jager 
et al., 2008). 
The prevalence and forecast data for AMD are available from numerous studies.  To 
date, one of the most comprehensive studies was published in 2004 by The Eye Diseases 
Prevalence Research Group (EDPRG), which estimated that in the year 2000, 1.47% of adults 
over the age of 40 in the United States, or approximately 1.75 million people, are affected by 
AMD, wet and/or dry (Friedman et al., 2004).  By 2020, only two decades later, AMD would affect 
nearly 3 million people.  With the aging of the population, this figure would surely shift upwards in 
the coming decades.  In a more recent publication, the overall prevalence of AMD may be slightly 
lower, given several modifiable factors such as smoking and the effects of changes in therapy for 
people at higher risk (genetic or modifiable) of developing advanced AMD (Klein et al., 2011). 
We will review aspects of AMD pathogenesis, though we note that the disease 
mechanism for dry AMD remains incompletely understood.  Generally, it is thought that 
abnormalities in Bruch’s membrane components (Johnson and Anderson, 2004), along with 
inflammation and chronic infection, may play important roles (Kalayoglu et al., 2005; Seddon et 
al., 2005a; Vine et al., 2005).  Several more specific mechanisms of disease, including ischemia 
of the photoreceptor and RPE due to decreased Bruch’s membrane/choroidal perfusion 
selectively damaging the macular region (Grunwald et al., 2005), primary RPE senescence, RPE 
cell apoptosis due to activation of components of the inflammatory and immune system, i.e., Toll-
like receptor 3 activation (Yang et al., 2008), and genetic polymorphisms in numerous disease 
susceptibility genes (Gorin, 2012) have been proposed.  Nevertheless, a combination of genetic 
and environmental factors related to one or more of these abnormalities may lead to the 
development of drusen, the pathognomonic feature of AMD.   
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The molecular basis of angiogenesis and wet AMD is better understood than that of dry 
AMD.  Since establishing the conceptual framework that choroidal neovascularization is tightly 
controlled by a substance that either promote or inhibit blood vessel formation/development, 
many groups have shown that a key angiogenic “Factor X,” later to be identified as vascular 
endothelial growth factor (VEGF), is responsible for retinal neovascularization associated with 
various forms of retinopathies (Aiello et al., 1994; Miller et al., 1997; Tolentino et al., 2002).  
Several VEGF isoforms have been identified, and VEGF-A, the one most associated with 
angiogenesis (Bhisitkul, 2006), has been the target of current, mainstay anti-VEGF therapies 
used in the treatment of wet AMD.  In this regard, there has been considerable success as the 
loss of vision due to poorly-controlled wet AMD has decreased substantially where treatment has 
become available and prevalent. 
AMD remains a complex, multi-factorial disease with many possible and likely genetic 
and environmental contributory factors.  This introduction does not attempt to cover the depth and 
scope of work done with the aim of better understanding AMD pathogenesis, but we hope it can 
provide a basis for understanding the main work that is to be presented in this thesis. 
 
The accumulation of iron in the retinal pigment epithelium in AMD 
 Work in the Dunaief lab using Perls’ staining identified increased iron deposition in the 
RPE/Bruch’s membrane underlying the macula region of AMD retinas compared to that of 
normal, age-matched controls (Hahn et al., 2003).  In a case report of a 72-year old patient with 
advanced geographic atrophy, the cells in the photoreceptor layer also exhibited strong labeling 
for iron as well as ferroportin, the only known exporter of iron, and ferritin, an iron storage protein 
(Dentchev et al., 2005).  Both ferroportin and ferritin have been found to be up-regulated in 
response to elevated iron levels in the mouse retina (Hahn et al., 2004a, 2004b). Taken together, 
these findings in patients and mice suggest a pathogenic role for iron not only in the RPE/Bruch’s 
membrane, but also in the neurosensory retina.  One logical possibility for iron-induced damage 
to retinal tissues is oxidative stress. 
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 Ferrous iron (Fe2+) participates in Fenton chemistry with peroxide, H2O2 to produce the 
ferric form of iron (Fe3+), and the highly reactive/damaging hydroxyl radical (OH•).  This implies 
that an increase in non-bound, labile iron concentration would lead to an increase in reactive 
oxygen species (ROS) that would impair RPE cell function.  In fact, increased iron in the retina 
can lead to lipid peroxidation of photoreceptors.  In turn, phagocytosis of such peroxidized outer 
segments by the RPE can damage the RPE membranes (Guajardo et al., 2003).  Furthermore, in 
vitro studies using iron-loaded ARPE-19 cells exhibited much decreased phagocytosis activity, 
interrupted cathepsin D processing, and reduced cathepsin D activity (Chen et al., 2009).   
 
The lack of ferroxidase expression leads to retinal degeneration 
 The conversion of ferrous to ferric iron requires the activity of proteins known as 
ferroxidases.  Four proteins with ferroxidase activity have been identified in mammals, which are 
ceruloplasmin, hephaestin, zyklopen, and amyloid precursor protein.  All four of these proteins 
have been localized in the mammalian retina, and the RPE seems to express all of them (Chen et 
al., 2010, 2003, 1997; Hahn et al., 2004a).   
Aceruloplasminemia(CP-/-) is a rare, adult-onset autosomal recessive condition caused by 
mutations in the ceruloplasmin gene on chromosome 3q (Harris et al., 1995).It was first reported 
that the patient had late-onset retinal and basal ganglia degeneration, the latter of which was 
associated with iron deposition as seen on magnetic resonance imaging.  Studies in the Dunaief 
lab have shown that a Caucasian patient with aceruloplasminemia had early-onset maculopathy 
as demonstrated by yellowish-white subretinal drusen-like lesions and RPE cell atrophy, which 
resemble some of the morphological features of AMD (Dunaief et al., 2005; Wolkow et al., 2011).  
The presentation of retinal and RPE degeneration in human patients with this disease, a primary 
disorder of iron metabolism, indicates that dysregulation of iron homeostasis may contribute to 
the retinal degeneration seen in the clinical presentation of AMD. 
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The ceruloplasmin gene-deficient mouse (Cp-/-) has been previously developed to better 
understand the role of the ferroxidase ceruloplasmin in CNS iron homeostasis.  On histology, the 
retinas of these mice show neurodegenerative changes in the inner nuclear layer, the main site of 
ceruloplasmin expression.  Many cells of this layer had condensed chromatin and darkened 
cytoplasm (Patel et al., 2002).  Since these changes are not drastic, a mouse with a combined Cp 
mutation and a sex-linked anemia (sla) mutation in the hephaestin gene, herein referred to as the 
double knockout (DKO), was developed by our laboratory.  These mice have an progressive, 
severe retinal degeneration accompanied by retinal iron accumulation (Hadziahmetovic et al., 
2008a; Hahn et al., 2004a).  In these studies, increased ferritin staining by immune-labeling was 
evident at 6 months of age, and Perls’ positive RPE cells were detected by 9 months.  Similar to 
AMD, ultra-structural analysis of the RPE shows undigested photoreceptor outer segments, 
indicating RPE dysfunction.  Bruch’s membrane integrity is also compromised, with the 
appearance of widely-spaced college in the sub-RPE space.  Most pertinent to our current work, 
increased RPE iron content in DKO mice leads to cellular autofluorescence and accumulation of 
complement component 3 (C3) in the RPE/Bruch’s membrane compartment.   
 
AMD as a genetic disease 
 Although many non-genetic and/or environmental factors have been implicated in AMD 
development, such as smoking, nutritional antioxidant levels, and omega-3 fatty acid intake, 
accumulating evidence suggests that genetic predisposition plays an important role in conferring 
AMD risk.  The heritability of AMD, or the relative contribution of genetic to non-genetic factors, is 
estimated at a relatively high value of between 45% and 70% (Seddon et al., 2005b). It is said 
that the genetics of AMD is unique among multi-factorial diseases in that several genetic loci 
confer strong effect sizes with reported odds ratios of >2.0 per risk allele.  For examples, strong 
risk variants in the CFH gene (Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005) on 
chromosome 1q32 and the ARMS2/HTRA1 genes (Jakobsdottir et al., 2005; Rivera et al., 2005) 
on chromosome region 10q24 were identified.  These were followed by numerous other risk 
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variants in complement genes and genes related to immunity, lipid metabolism, and extracellular 
matrix homeostasis (Grassmann et al., 2014). 
In recent years, there has been an impressive output of genome-wide association studies 
(GWASs) involving a large number of subjects in the field of AMD genetics.  An international 
multicenter meta-analysis involving more than 18 individual GWAS datasets, which combined 
included more than 17,000 cases of AMD and 60,000 control patients (Fritsche, 2013), 
contributed to defining an association between AMD and genetic variants in a total of 19 
chromosomal regions (Table 1.1) .  The genes that lie in these regions belong to different 
categories of biological processes or signaling pathways.  Some of the major categories, listed in 
Table 1.1, include extracellular matrix organization, angiogenesis, regulation of inflammation, 
cholesterol metabolism, and above all, complement activation (Weber et al., 2014).  Cumulatively, 
these genetic findings may enable, through extensive downstream studies, the establishment of 
possible causal relationships between the development of AMD and a host of biological 
processes or signaling pathways. This may be particularly relevant for complement system of 
innate immunity, which is the focus of the thesis work herein. As can be inferred, a better 
understanding how aberrant complement activation contributes to the disease phenotype and 
progression of AMD may prove to be useful for both genetic risk prediction/stratification and the 
development of novel targeted therapies. 
 
The association of complement and AMD, with a focus on C3 
 Complement, or sometimes referred to as the “complement cascade,” is an arm of the 
innate immune system consisting of a complex network of plasma proteins that interact and 
cooperate to provide defenses against microbial invasion and maintain healthy tissue integrity.  
The major steps involved in complement activation are initiation, formation of the C3 convertase 
protein complex, cleavage of the C3 molecule, formation of a C5 convertase complex, cleavage 
of the C5 molecule, and formation of the membrane attack complex (MAC) as part of the terminal  
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Table 1.1 Summary of common AMD associated variants (adapted from Fritsche, 2013). 
SNP 
Candidate genes 
in region 
Biological process 
Frequency of risk 
variant in AMD 
patients 
Odds 
ratio 
95% CI 
rs10737680/A CFH Complement activation 64% 2.43 (2.39 to 2.47) 
rs13081855/T COL8A1 Extracellular matrix organization 10% 1.23 (1.17 to 1.29) 
rs6795735/T ADAMTS9 Extracellular matrix organization 46% 1.10 (1.07 to 1.14) 
rs4698775/G CFI Complement activation 31% 1.14 (1.10 to 1.17) 
rs429608/G C2/CFB Complement activation 86% 1.74 (1.68 to 1.79) 
rs943080/T VEGFA Angiogenesis 51% 1.15 (1.12 to 1.18) 
rs3812111/T COL10A1 Extracellular matrix organization 64% 1.10 (1.07 to 1.14) 
rs3130783/A 
DDR1 Extracellular matrix organization 
79% 1.16 (1.11 to 1.20) 
IER3 Regulation of inflammatory 
processes/apoptosis 
rs13278062/T TNFRSF10A Activation of NF-κB 
kinases/apoptosis 
48% 1.15 (1.12 to 1.19) 
rs334353/T TGFBR1 Extracellular matrix 
organization/angiogenesis 
73% 1.13 (1.10 to 1.17) 
rs10490924/T 
HTRA1 Extracellular matrix organization 
30% 2.76 (2.72 to 2.80) 
ARMS2 Unknown 
rs9542236/C B3GALTL Protein glycosylation 44% 1.10 (1.07 to 1.14) 
rs8017304/A RAD51B DNA repair/apoptosis 61% 1.11 (1.08 to 1.14) 
rs920915/C LIPC Cholesterol/LDL/HDL metabolism 48% 1.13 (1.09 to 1.17) 
rs1864163/G CETP Cholesterol/LDL/HDL metabolism 76% 1.22 (1.17 to 1.27) 
rs2230199/C C3 Complement activation 20% 1.42 (1.37 to 1.47) 
rs4420638/A APOE Cholesterol/LDL/HDL metabolism 83% 1.30 (1.24 to 1.36) 
rs5749482/G 
TIMP3 Extracellular matrix 
74% 1.31 (1.26 to 1.36) 
SYN3 Neurotransmitter secretion 
rs8135665/T SLC16A8 Membrane transport 21% 1.15 (1.11 to 1.19) 
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complement pathway.  On the most basic level, three complement pathways (classical, lectin, 
and alternative) can each be uniquely activated by specific inciting factors all with the end result 
of C3 activation, which promotes pro-inflammatory reactions and activation the terminal 
complement pathway leading to MAC formation (Sahu and Lambris, 2001). 
 The importance of complement biology in AMD is, at this point, well established.  Without 
undertaking a review of complement-related diseases, we note that inherited complement 
deficiencies, such as mutations in components of the cell lytic, terminal pathway increases a 
patient’s susceptibility to Gram-negative bacterial infections; on the other hand, mutations that 
impair the function of complement cascade regulatory proteins have been linked to many 
autoimmune diseases, such as systemic lupus erythematosus (SLE).   Returning to the eye and 
as described above in the AMD genetics section of this Chapter, variants in genes encoding 
complement components and regulatory proteins (Table 1.1) confer increased disease risk.  It is 
thus reasonable to hypothesize that the decreasing ability of complement to maintain healthy 
tissue as a result of its dysregulation likely contributes to the pathogenesis of AMD.  It is telling 
that some well-studied iron-related loci have not been implicated in AMD (i.e. HFE for high iron 
and TMPRSS6 loss of function for low iron).  Perhaps this is because these loci by themselves 
have low disease penetrance compared to complement gene polymorphisms, but that as this 
thesis will show, iron dysregulation may serve as a crucial component that drives complement 
dysregulation in AMD.  
 Among the three complement pathways, it is widely accepted that the alternative 
complement pathway is the most important in the AMD disease context.  The alternative pathway, 
interestingly, is continuously activated by a spontaneous hydrolysis of the internal thioester bond 
in C3 to form C3(H2O).  Because this species can fulfill the same role as C3b in participating in 
the formation of the C3 convertase, there is a low-level of baseline pathway activity, a 
phenomenon also known as “tick-over” (Pangburn, 1981).  C3(H2O) binds to the Bb portion of 
complement factor B (CFB), which itself is cleaved by the complement serine protease factor D  
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Figure 1.3 The alternative complement pathway and its regulators (fluid phase and membrane-
bound). The alternative pathway is central to the pathogenesis of AMD.  Genetic variants in 
complement component and regulator genes result in altered protein function and thus altered 
dynamics of the system. The  symbol (red) indicates decay-accelerating function (of 
convertase) or inactivation (of C3b to iC3b), + (green) indicates enzymatic action, and – 
(maroon) indicates inhibitory action.  Figure is adapted from Bradley et al., 2011. 
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(CFD).  The Ba fragment that results from CFD-mediated splitting of CFB is most likely retained in 
the fluid phase, and provides a suitable marker for alternative pathway activation (Kolb et al., 
1989).  The C3 convertase, C3(H2O)Bb, cleaves C3 into C3a and C3b and activates the 
molecule.  To amplify this reaction, C3b feeds into the positive feedback loop by binding to Bb 
and forms more C3 convertase enzyme complexes.  A diagram illustrating these fundamental 
aspects of the alternative complement pathway is provided in Fig. 1.3 (Bradley et al., 2011).  C3b 
is also deposited on cell/tissue surfaces and can be further processed to C3d.  Given the 
continuous manner by which the alternative pathway is activated, the key role of inhibitory 
regulators is to prevent inappropriate over-activation and damage to self-tissues. 
 In AMD drusen deposits, almost all alternative complement pathway proteins have been 
identified, including CFH, C3, and the derivatives of its activation and processing.  Furthermore, 
the fragment C3d and the Ba fragment of CFB, collectively considered as chronic complement 
activation markers, as well as and CFD, are significantly increased the blood plasma in AMD 
patients (Scholl et al., 2008).  However, the interaction or correlation between systemic 
complement activation and ocular pathology is not well characterized.  Although CFH is the first 
and arguably the most important of the complement cascade members to be genetically 
implicated in AMD, we now turn our focus to C3, the main subject of our study.  It must be noted 
that C3 is the central component of the entire complement cascade.  One of the most strongly 
associated genetic variants in C3, rs2230199 (R80G), results in a change in protein electrical 
charge as evidenced by the differentiation of fast and slow electrophoretic variants.  Although the 
variant was mapped to the C3b portion of the precursor protein, which affects renal graft survival, 
the functional implications of the polymorphism on AMD pathogenesis remains, as yet, unclear 
(Yates et al., 2007).  More recently, two reports have identified a rare variant in C3 that is 
associated with advanced AMD.  This variant, rs147859257 (K155Q), is rarer than the 
aforementioned rs2230199.  The rare variant is associated with ~2.91-fold increased risk for 
macular degeneration, and the resulting C3b variant is functionally hypothesized to have reduced 
binding to CFH (Zhan et al., 2013).  In the companion paper that also characterized this rare 
variant, the co-incubation of CFH, CFI, and K155 (wild-type) C3 protein displayed much more 
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efficient cleavage of the C3 protein alpha-chain compared to the parallel experiment containing 
the Q155 (variant) protein (Seddon et al., 2013). 
Given the wealth of genetic evidence implicating complement gene polymorphisms in 
AMD, it is prudent to also consider the effect of environmental exposures to the activities of the 
complement cascade.  One particularly promising and fruitful line of research in this area has 
been smoking, a factor that has been found to increase AMD risk consistently.  On the 
epidemiology front, the Age-Related Eye Disease Study (AREDS) reported an odds ratio of 1.6 
for wet AMD and 1.8 for geographic atrophy when comparing people who had smoked >10 pack-
years to those who had no smoking history (2005); The Blue Mountains Eye Study found that 
current smokers had a relative risk of 3.9 for advanced AMD compared with non-smokers (Tan, 
2007).  On the functional front, cigarette smoke has been shown to modify the C3 protein in vitro 
such that it is less susceptible to inactivation by CFH and CFI (Kew et al., 1985);  More recently, 
cigarette smoke has been shown to increase expression and activation of C3 in cultured ARPE-
19 cells (Kunchithapautham et al., 2014).  A prevailing hypothesis for some of these findings is 
that smoke-associated oxidative stress may lead to the aberrant over-activation of complement, 
as seen with modifiable proteins and increased gene expression.  Which other environmental 
factors can affect oxidative stress?  Iron, the subject of our longstanding interest, logically may be 
one answer to this question. 
 
TGF-β signaling in context and its role in disease 
 The Transforming Growth Factor-β (TGF-β) superfamily is a group of highly conserved 
growth and differentiation factors that play pleiotropic roles in cell proliferation, differentiation, 
morphogenesis, tissue homeostasis, and tumorigenesis (Massague, 2012).  The classical 
category of factors, for which the superfamily is named, is the TGF-β ligand.  These are secreted 
molecules that contain 7 conserved Cys residues in the primary sequence.  Two TGF-β 
polypeptides form a dimer, forming inter- and intra-subunit disulfide bonds in a tight structure 
called the “cysteine knot” (Shi and Massagué, 2003).  The TGF-β ligand is initially synthesized as 
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an approximately 400 aa precursor that is cleaved to form the mature protein containing a pro-
peptide.  Once this pro-peptide is removed, the TGF-β is rendered biologically active (Massagué, 
1998). 
 TGF-β signaling commences with ligand binding to the TGF-β receptor complex, which is 
composed of the type II and type I transmembrane serine/threonine kinase receptors.  After 
ligand-induced conformational changes, the constitutively active type II receptor phosphorylates 
the type I receptor, which in turn phosphorylates the receptor-regulated Smad proteins, or R-
Smads known as Smad2 or Smad3 (Feng and Derynck, 2005).  In canonical TGF-β signaling, 
phosphorylated R-Smads interacts with the common mediator Smad (co-Smad) such as Smad4, 
co-translocate to the nucleus, where they recruit other co-activators and/or co-repressors to 
modulate target gene expression (Fig. 1.4).  To end the signaling effect and Smad-mediated 
transcription, cells employ a number of different means, including but not limited to phosphatase 
action to remove the phosphorylation of Smad C-terminal residues (Bruce and Sapkota, 2012) 
and ubiquitylation for targeted turnover of the R-Smad molecule itself (Gao et al., 2009).  As such, 
Smad proteins are a central pillar of TGF-β superfamily signaling, transducing the signals 
conveyed by ligand binding to specific receptors. 
 Smad proteins may not only act as an effector of canonical TGF-β ligand-induced 
signaling inputs.  More and more interesting facets of Smad biology have come to light in recent 
years, resulting in a new understanding Smad protein biology.  The R-Smad protein has two 
conserved domains, one N-terminal and the other C-terminal, designated as MH1 and MH2 
domains, respectively.  Between the MH1 and MH2 domains lie a proline-rich linker, a region that 
is divergent in sequence and length (Shi and Massagué, 2003; Wang et al., 2009).  This linker 
region may be a hub for integrating varied regulatory inputs (Massague, 2012), and studies have 
demonstrated the Smad3 protein harbors four putative phosphorylation sites in the linker region: 
Thr 179 (T179), Ser 204 (S204), Ser 208 (S208), and Ser 213 (S213).  Quite importantly, the 
phosphorylation of these linker region residues appears to be highly context dependent, with  
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Figure 1.4 The Transforming Growth Factor-β (TGF-β) signal transduction pathways. TGF-β is 
secreted in an inactive latent form that can be activated by proteases. In canonical signaling, 
dimerized TGF-β ligand induces a heterodimerization of TGF-β types I and II receptors. Active 
TGF-beta type I receptors act on downstream effectors, including the receptor SMADs (R-Smads) 
that are phosphorylated on the C-terminus to permit binding to the co-Smad, Smad4, and nuclear 
localization. Nuclear Smad complexes bind with low affinity to specific SMAD binding elements 
(SBEs) in the promoter sequences of regulated genes. Transcription complexes are formed with 
transcriptional binding partners and transcriptional activators/ inhibitors to specifically induce or 
repress gene expression. TGF-β can also activate other pathways: Akt, JNK, p38, Erk, etc. as 
part non-canonical signaling.  Figure and legend adapted from Rich, 2003. 
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different kinases and/or different conditions yielding varied patterns of phosphorylation and with 
those, downstream effects.  For examples, cyclin-dependent kinase (CDK) 2/4 phosphorylates 
Smad3 at the T179 and S213 in the linker region (Matsuura et al., 2004) and epidermal growth 
factor (EGF)-induced ERK1/2 activation  results in the phosphorylation of T179, S204, and S208, 
with S208 as the purported best ERK1/2 site of action (Matsuura et al., 2005).  Furthermore, 
besides phosphorylating the C-terminal residues of Smad3, as defined in canonical signaling, 
TGF-β can induce a rapid phosphorylation of the linker region residues, adding a layer of 
complexity to the paradigm of canonical signaling.  This may be called non-canonical TGF-β 
signaling.  However,  
in this case the ligand receptor does not itself phosphorylate the Smad3 linker, but instead 
recruits other kinases, such as those in the CDK family, to mediate C-terminal-dependent linker 
phosphorylation (Wang et al., 2009).  Interestingly, the  Smad3 linker region may also physically 
interact with co-activators or co-repressors (i.e. p300), thereby modulating Smad3 C-terminal 
phosphorylation-dependent gene expression (Wang et al., 2009).  This level of cross-talk most 
likely allows Smad3 to generate a much larger range of transcriptional activities, which translates 
to a large set of distinct biological responses. 
 The role that iron may play in modulating Smad3 action in the process of up-regulating 
C3 expression will be examined in the next Chapter.  In these studies, iron, not TGF-β ligand, 
stimulates Smad3 activity via a non-canonical pathway; meanwhile, iron suppresses Smad3-
mediated canonical signaling activity.  To our knowledge, this is the first detailed study on how 
iron modulates TGF-β signaling, which sets it apart from the majority of the literature in the field, 
which focuses, rightly, on ligand-induced signaling. 
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CHAPTER 2 
Preamble 
This chapter contains the manuscript entitled “iron-induced complement component 3 
(C3) up-regulation via non-canonical TGF-β signaling in the retinal pigment epithelium,” which 
represents the main work of my thesis.  Some information in the Abstract and Introduction may be 
slightly redundant from those presented in Chapter 1, but it is our opinion that these concepts are 
worth re-visiting prior to the presentation of experimental data. 
The manuscript herein (written entirely by me) was submitted to the Journal of Biological 
Chemistry on 17 February 2015; it was revised, re-submitted, and accepted for publication on 23 
March 2015.  The abstract and all subsequent sections have been preserved from the 
manuscript. 
 
Abstract 
Dysregulation of iron homeostasis may be a pathogenic factor in age-related macular 
degeneration (AMD).  Meanwhile, the formation of complement-containing deposits under the 
retinal pigment epithelial (RPE) cell layer is a pathognomonic feature of AMD.  In this study, we 
investigated the molecular mechanisms by which C3, a central protein in the complement 
cascade, is up-regulated by iron in RPE cells. Modulation of TGF-β signaling, involving ERK1/2, 
SMAD3, and CCAAT/enhancer-binding protein-δ (C/EBP-δ), is responsible for iron-induced C3 
expression. The differential effects of spatially distinct SMAD3 phosphorylation sites at the linker 
region and at the C-terminus determined the up-regulation of C3. Pharmacologic inhibition of 
either ERK1/2 or SMAD3 phosphorylation decreased iron-induced C3 expression levels.  
Knockdown of SMAD3 blocked the iron-induced up-regulation and nuclear accumulation of 
C/EBP-δ, a transcription factor that has been shown previously to bind the basic Leucine Zipper 1 
(bZIP1) domain in the C3 promoter.  We show herein that mutation of this domain reduced iron-
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induced C3 promoter activity.  In vivo studies support our in vitro finding of iron-induced C3 up-
regulation. Mice with a mosaic pattern of RPE-specific iron overload demonstrated co-localization 
of iron-induced ferritin and C3d deposits. Humans with aceruloplasminemia causing RPE iron 
overload had increased RPE C3d deposition. The molecular events in the iron-C3 pathway 
represent therapeutic targets for AMD or other diseases exacerbated by iron-induced local 
complement dysregulation. 
 
Introduction 
Dysregulation of iron homeostasis may be an etiologic factor in several neurodegenerative 
disorders such as age-related macular degeneration (AMD)ǁ (Dunaief, 2006), although the 
detailed mechanisms by which iron acts as a driver of AMD-like pathology have not been 
reported.  AMD is considered a chronic, localized inflammatory disease (Johnson et al., 2001; 
Zipfel et al., 2010) with a genetic component (Grassmann et al., 2014).  Several genetic factors 
that confer major risk for AMD are polymorphisms within complement component genes 
(Edwards et al., 2005; Gold et al., 2006; Haines et al., 2005; Klein et al., 2005; Seddon et al., 
2013; Yates et al., 2007).  Since complement dysregulation can lead to inflammatory reactions 
(Markiewski and Lambris, 2007; Morgan et al., 2005), both genetic and environmental factors 
may work concurrently to determine the activity of the complement cascade in the outer-retinal 
milieu. AMD is characterized by primary pathology in the retinal pigment epithelium (RPE) 
monolayer and the formation of sub-RPE deposits called drusen.  In human drusen samples, both 
C3 and C3 activation fragments were identified (Anderson et al., 2002).  C3, the central molecule 
of the complement cascade that includes the classical, alternative, and lectin pathways, is 
activated by numerous inciting factors that require a rapid inflammatory reaction (Markiewski and 
Lambris, 2007; Sahu and Lambris, 2001).  In AMD, the aberrant activation of the alternative 
pathway and the resultant release of inflammatory mediators are involved in drusen formation 
(Anderson et al., 2002).  In the alternative pathway, C3 activation is under the control of Factor B, 
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a key pathway component, and Factor H, a potent negative regulator, among others (Chen et al., 
2008; Pickering et al., 2002).  Both Factor B and Factor H are expressed by the RPE cell (Chen 
et al., 2007, 2008; Coffey et al., 2007).  Increased Factor B levels are accompanied by increased 
C3 expression and activation in aged mouse RPE (Chen et al., 2008).  The interaction between 
C3 and Factor H is supported by the finding that C3b is a major physiological ligand of Factor H 
(Perkins et al., 2012).  Furthermore, both C3 and Factor H are genetically implicated as 
contributory factors to AMD etiology (Klein et al., 2005; Yates et al., 2007). 
 
Previous studies have shown elevated total iron levels in the RPE/Bruch’s membrane complex as 
well as photoreceptors in the human macula of post-mortem dry and wet AMD eyes compared to 
those of healthy controls (Hahn P et al., 2003).  The iron-containing species in these samples 
identified by histochemical and chelation tests comprise both loosely bound, chelatable iron and 
non-chelatable iron components.  The non-chelatable iron components may be iron derivatives 
that are incorporated into, and are essential for, the function of reactive oxygen species (ROS)-
producing enzymes (Dixon and Stockwell, 2014).  The chelatable iron is capable of directly 
generating ROS via Fenton chemistry.  Evidence exists that ROS can in turn damage iron-
containing proteins to produce more labile iron (Dixon and Stockwell, 2014; Flint et al., 1993), 
suggesting the interchangeability of non-chelatable and chelatable iron.  Thus, it is reasonable to 
study the biological impact of an increased intracellular labile iron pool (LIP) on complement 
regulation in the RPE. 
 
Our group has demonstrated previously increased RPE iron levels in mice with knockout of the 
Cp gene (Cp-/-) and a naturally occurring Sla mutation in the Heph gene (HephSla/Sla or HephSla/Y), 
referred to as the double knockout (DKO) mouse model (Hadziahmetovic et al., 2008b; Hahn et 
al., 2004a).  When compared to the wild-type mice, these DKO mice exhibited some pathological 
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features of AMD, and the generalized high iron level in retina and RPE/choroid were associated 
with an accumulation of sub-RPE activated C3 fragments (Hadziahmetovic et al., 2008b).  Our 
group has also shown that systemic administration of the iron chelator deferiprone decreased 
murine retinal C3 mRNA levels in a light-induced degeneration model (Song et al., 2012a) and 
RPE C3 mRNA levels in a sodium iodate-induced degeneration model (Hadziahmetovic et al., 
2012a).  These findings suggest that diminishing iron levels may reduce retinal complement 
expression.  However, whether and how an increase in LIP within RPE cells is capable of 
triggering endogenous C3 activation are, as yet, unknown.   
 
In cultured RPE cells, we found that iron exposure increases both C3 mRNA and protein levels. 
To understand the underlying molecular events, we first pursued a bioinformatics approach using 
a gene expression microarray, which identified the TGF-β signaling superfamily as the 
pathway(s) most strongly affected by iron.  Interestingly, the TGF-β Receptor Type I gene, 
TGFBR1, is genetically associated with advanced AMD (Fritsche, 2013) and elevated urinary 
TGF-β1 protein levels are associated with early AMD (Guymer et al., 2011).  In canonical TGF-β 
signaling, TGF-β ligands bind to receptor serine/threonine kinases that phosphorylate 
transcription factors SMAD2 and SMAD3 at the C-terminal SSXS motif (Feng and Derynck, 
2005). While non-phosphorylated SMAD proteins shuttle in and out of the nucleus dynamically, 
upon phosphorylation, SMAD2/3 docks with SMAD4 and undergoes nuclear translocation.  Once 
in the nucleus, this complex recruits co-factors to form a larger complex and differentially 
regulates target gene expression.  In this study, we identified in cultured human RPE cells an 
iron-induced, non-canonical TGF-β pathway leading to C3 up-regulation.  Corresponding in vivo 
studies showed that deposition of the C3 activation product C3d is spatially associated with iron 
overloaded RPE cells. 
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Experimental procedures 
Cell Culture and Cell Treatment Reagents—ARPE-19 cells from the American Type Culture 
Collection (ATCC, Manassas, VA) were cultured in 1:1 DMEM/F12 (Invitrogen, Grand Island, NY) 
supplemented with 10% FBS (HyClone, Logan, UT).  Once confluent, cells were maintained in 
medium with 1% FBS for 4 weeks prior to experiments to obtain mature monolayers 
(Kunchithapautham et al., 2014).  One day prior to experiments, cells were placed in serum-free 
medium to deplete residual serum complement components.  Iron in the form of Ferric 
Ammonium Citrate (FAC; MP Biomedicals, Santa Ana, CA), dissolved in serum-free medium, was 
used to treat cells for the indicated times.  Alamar Blue reagent for cell viability was from 
Invitrogen.  Transition metals suitable for cell culture were from Sigma (St. Louis, MO).  Purified 
apo- and holo-Transferrin (Tf) were from Millipore (Billerica, MA).  Expression plasmids pCS2 
FLAG-SMAD3 (Kretzschmar et al., 1999), pCS2 FLAG-SMAD3 (EPSM) (Kretzschmar et al., 
1999), and pCS2 FLAG SMAD3 EPSM A213S (Gao et al., 2009) were gifts from Joan Massagué 
(Addgene plasmids #14052, 14963, 27113).  Pharmacologic inhibitors, recombinant proteins, and 
neutralizing antibodies were obtained as follows: PD98059, U0126, SB202190, SP600125, and 
human recombinant TGF-β1, β2, β3 (Cell Signaling, Danvers, MA); SIS3 (Millipore); SB431542 
(Tocris, Minneapolis, MN); anti-TGF-β1/2/3 antibody and isotype control (R&D Systems, 
Minneapolis, MN).   
 
RNA Extraction, Quantitative RT-PCR, Microarray Processing and Data Analysis—Total RNA 
was isolated using QIAzol® reagent and the miRNeasy Mini Kit from Qiagen (Valencia, CA).  
Quantitative reverse transcriptase-PCR (qRT-PCR) using the standard ΔΔCt method was 
performed using Taqman primers (Applied Biosystems, Waltham, MA) listed in Table 2.1, with 
18S rRNA as the internal control.  Microarray processing and data analysis services were 
provided by the Penn Molecular Profiling Facility using the Affymetrix GeneChip® Human Gene 
2.0 ST Array (Affymetrix, Santa Clara, CA).  For each group, untreated and FAC-treated, three  
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Table 2.1 Taqman® qRT-PCR primers 
Gene name Symbol Catalog number 
complement component 3 (human) C3 Hs01100879_m1 
transferrin receptor (human) TFRC Hs00174609_m1 
plasminogen activator inhibitor type 1 (PAI-1; human) SERPINE1 (PAI-1) Hs01126607_g1 
transforming growth factor, beta 1 (human) TGFB1 Hs00998133_m1 
CCAAT/enhancer binding protein (C/EBP), delta (human) CEBPD Hs00270931_s1 
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independent arrays were performed, probing >40,000 Transcript IDs from more than 24,800 
genes.  Processing steps were conducted as described in the Ambion WT Expression Manual 
and the Affymetrix GeneChip Expression Analysis Technical Manual.  For data analysis, probe 
intensity (.cel) files were imported into Partek Genomics Suite (v6.6, Partek Inc., St. Louis, MO), 
where RMA normalization was applied yielding log2-transformed intensities. These values were 
tested for differential expression using Significance Analysis for Microarrays (SAM; samr v2.0, 
Stanford University) (Tusher et al., 2001), yielding a fold-change and q-value (false discovery 
rate) for each transcript.  For a transcript to be considered for input into DAVID Bioinformatics 
Resources 6.7 (http://david.abcc.ncifcrf.gov; accessed February 2015) for pathway analysis, the 
thresholds of fold-change ≥1.5 (up or down) and q-value ≤10% were applied.  The KEGG and 
BioCarta pathway mapping databases as well as GOTERM_BP_FAT biological processes 
database were included within the analysis.  The top pathways/processes were determined by 
setting a corrected false discovery rate (Benjamini-Hochberg) <10%.  The complete array dataset 
can be accessed in the Supplemental Table at the following URL: 
http://www.jbc.org/content/early/2015/03/23/jbc.M115.645903/suppl/DC1. 
 
Whole Cell Protein Extraction, Cell Compartment Protein Extraction and Western Blotting — 
Whole cell protein lysates were extracted using Laemmli SDS Lysis Buffer supplemented with 
Protease/Phosphatase inhibitor cocktail and PMSF (Cell Signaling) according to standard 
methods.  Lysates were sonicated for 10s prior to quantification with the 660nm protein assay 
(Pierce, Rockford, IL). For each sample, 30 µg of protein were loaded onto a 4-12% Bis-Tris gel 
for Western blotting.  Non-nuclear (cytoplasmic, membranous, cytoskeletal) and nuclear protein 
lysates were extracted using the Qproteome® cell compartment kit (Qiagen) according to 
manufacturer’s instructions.  Primary antibodies used are as follows: anti-p-ERK1/2, anti-ERK1/2, 
anti-p-SMAD2 (S245/250/255), anti-GAPDH, and anti-α-tubulin clone 11H10 (Cell Signaling); 
anti-SMAD3, anti-FLAG M2, and anti-Actin AC-40 (Sigma); anti-p-SMAD3 (S213) (Assay Biotech, 
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Sunnyvale, CA); anti-Transferrin Receptor (TFRC; Invitrogen); anti-p-SMAD3 (S423/425) and 
anti-Lamin B1 (Abcam, Cambridge, MA); anti-C/EBP-δ (clone L46–743.92.69) was provided by 
BD Biosciences Pharmingen (San Jose, CA) as an outcome of an Antibody Co-development 
Collaboration with the NCI.  Secondary antibodies IRDye® 680RD Donkey anti-Rabbit and 
800CW Donkey anti-Mouse (LI-COR Biosciences, Lincoln, NE) were used in combination when 
possible for two-channel infrared detection with an Odyssey imager.  ImageJ Software 1.46r was 
used for band densitometry. 
 
Knockdown of SMAD3 using Lentiviral Vectors—This was performed per MISSION shRNA’s 
instructions (Sigma).  Briefly, ARPE-19 cells were seeded overnight to 70% confluence prior to 
treatment with lentiviral transduction particles (Sigma) that express shRNA targeting SMAD3 
transcripts (sh-SMAD3).  All particles used, including controls are listed in Table 2.2.  Cells were 
used for qRT-PCR 72h post-transduction, without selection or puromycin was used to select for 
stably transduced cells for 2-3 passages prior to qRT-PCR and Western blotting. 
 
Plasmid Construction, Transfection and Dual Luciferase Assays—DNA fragments consisting of 
four different sized, overlapping sequences of the C3 gene promoter, flanked by 5’ and 3’ MluI 
and BglII sites, respectively, were amplified by the Q5® High-Fidelity DNA Polymerase from New 
England BioLabs (NEB, Ipswich, MA).  The fragments, which are approximately 500 bp (-481 to 
+52), 1.0 kb (-1078 to +52), 1.5 kb (-1555 to +52), and 2.0 kb (-2047 to +52), were cloned into the 
pCR-Blunt II TOPO vector using the Zero Blunt TOPO kit (Life Technologies, Grand Island, NY) 
according to the product instructions.  The bZIP1 and bZIP2 mutant fragments, with the same 
base substitutions as previously reported (Juan et al., 1993), were generated using the Q5® Site-
Directed Mutagenesis Kit (NEB).  All primers are listed in Table 2.3.  Once sequence-verified, the 
fragments were sub-cloned into the pGL3-Basic Vector (Promega, Madison, WI) for luciferase 
assays.  ARPE-19 cells at 80% confluence, grown in complete medium with no antibiotics, were 
transfected with either empty or promoter-inserted pGL3 vector using the reagent Lipofectamine  
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Table 2.2 Sigma MISSION® lentiviral transduction particles 
Product name Abbreviation used Catalog number 
pLKO.1-puro empty vector control Vector SHC001V 
pLKO.1-puro non-mammalian shRNA control sh-Null SHC002V 
pLKO.1-puro-CMV-TurboGFP™ Positive Control t-GFP (not shown) SHC004V 
pLKO.1-puro SMAD3 shRNA sh-SMAD3 SHCLNV-NM_005902 TRCN0000330127 
 
 
Table 2.3 PCR primers used to generate C3 promoter fragments 
Fragment Forward primer (5'-3') Reverse primer (5'-3') 
500 bp/WT ACGTACGCGTAGTTTCTGTGCTGGGCTC ACGTAGATCTGACAGTGCAGGGTCAGAG 
1 kb ACGTACGCGTCTACTTGGGTGGTTGAGC ACGTAGATCTGACAGTGCAGGGTCAGAG 
1.5 kb ACGTACGCGTGAGGCAGGAGAATTGTTT ACGTAGATCTGACAGTGCAGGGTCAGAG 
2kb ACGTACGCGTGCAGGGCTCATAAGTGTG ACGTAGATCTGACAGTGCAGGGTCAGAG 
500 bp/bZIP1 AATGGTATTGTGTCGACTGGGGCAGCC TCCTAAGCTTTTCAGTCC 
500 bp/bZIP2 GAAAAGCTTATCGCGAGGTATTGAGAAATCTGGGGCAGCCCCAAAAGG AGTCCCTGGGGCCAACAT 
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LTX (Life Technologies) at 2:1 LTX:DNA ratio for 4h before initiation of FAC treatment.  
Luciferase activity was then determined with the Dual-Luciferase reporter assay system kit 
(Promega) according to manufacturer’s protocols.  Luminescence was read for 1.5s by an Infinite 
M200 Pro plate reader (Tecan Systems, Morrisville, NC). 
 
ELISA—Detections of secreted C3 precursor protein (Abcam), C3a (BD Biosciences) and Factor 
B fragment Ba (Quidel, San Diego, CA) in ARPE-19 cell culture conditioned media were 
performed per each manufacturer’s instructions.  The conditioned media used for C3 assay did 
not require concentration, but those for C3a and Ba required an approximately 70-fold 
concentration for detection in the standard range.  Amicon Ultra-15 centrifugal filters with a 3 kDa 
molecular weight cutoff membrane (Millipore) were used for media concentration.  
 
Immunofluorescence of Human Aceruloplasminemia Retina Paraffin Sections and Mouse Retinal 
Cryosections—Ocular tissue from a 60 year-old male donor with aceruloplasminemia was 
prepared as paraffin sections, as described in a previous publication, in adherence to the tenets 
of the Declaration of Helsinki (Wolkow et al., 2011).  The paraffin sections were stained with anti-
human C3d antibody (1:100, Abcam).  Generation of the systemic ceruloplasmin null, bestrophin 
promoter-driven cre recombinase, hephaestin floxed/floxed mouse on a C57BL/6 background 
(Bcre+, Cp-/-, HephF/F) has also been described in a previous publication (Wolkow et al., 2012).  
Background-matched C3 null (C3-/-) mice were provided by Wenchao Song (University of 
Pennsylvania).  All mice were handled in accordance with the Institutional Animal Care and Use 
Committee of the University of Pennsylvania.  Retina cryo-sections of 10 μm thickness derived 
from 12 month old-mice were used for immuno-labeling studies.  The primary antibodies used 
were rabbit anti-L-ferritin clone F-17 at a 1:100 dilution (generous gift from Paolo Arosio, 
Università Degli Studi di Brescia, Brescia, Italy) and goat anti-mouse C3d at a 1:100 dilution 
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(R&D Systems).  Slides were examined on a Nikon Eclipse 80i microscope, and images were 
acquired using NIS-BR Elements v4.1 software (Nikon, Melville, NY). 
 
Statistics—All experiments were performed in at least triplicate, with mean ± SEM reported for 
each comparison group. The means were analyzed using either a two-tailed Student’s t-test or a 
one-way ANOVA, followed by a Bonferroni post hoc test (Prism 5.0; GraphPad Software, San 
Diego, CA). 
 
Results 
Iron induced the expression of endogenous C3 in ARPE-19 cell 
In a previous publication we have shown that photo-oxidative stress in mouse RPE cells can lead 
to elevated C3 mRNA levels (Hadziahmetovic et al., 2012b).  These changes are accompanied 
by altered expression of iron regulatory proteins.  More directly, a mouse model of retinal iron 
overload, Cp-/-Hephsla, exhibited deposition of activated C3 fragments in the basolateral RPE and 
Bruch’s membrane (Hadziahmetovic et al., 2008b).  Since C3 is a central player in the 
complement cascade, here we investigated if iron can specifically induce C3 transcription and 
translation in the RPE cell.  Using the human ARPE-19 cell line differentiated in low serum for 
one month, then cultured in serum-free medium, we determined that the viability of these cells 
decreased by 30% but remained stable at all iron (ferric ammonium citrate; FAC) doses in the 25 
µM to 1 mM range  (Fig. 2.1A).  In this same analysis, transferrin receptor (TFRC) mRNA levels 
decreased by at least 50% in the same dose range (Fig. 2.1B), indicating an increase of the LIP 
and an intact iron regulatory axis.  Concurrently, the C3 mRNA levels increased by 3 to 4-fold 
relative to untreated cells (Fig. 2.1C).  In a corresponding experiment, the C3 protein levels in the 
conditioned medium were found to increase 2 to 3-fold within the range of FAC used (Fig. 2.1D).  
Renewal of culture medium and continued treatment with FAC beyond 2d (i.e. 4d and 8d),  
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Figure 2.1A Viability of cells grown as one-month differentiated monolayers and treated with FAC 
at increasing doses for 2d.  Viability is decreased with 25µM iron treatment compared to 
untreated but remains stable for higher doses examined.  Data are expressed as mean ± SEM 
(error bars), with n ≥3 using the following statistical notations: * p≤0.05; **, p≤0.01; ***, p≤0.001; 
****, p≤0.0001; these notations are consistent in all subsequent figures within Chapter 2. 
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Figure 2.1B TFRC mRNA with increasing FAC treatment doses for 2d.  The mRNA levels are 
decreased with 25µM iron treatment compared to untreated but remain stable for higher doses 
examined. 
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Figure 2.1C C3 mRNA levels with increasing FAC treatment doses for 2d.  The C3 mRNA levels 
are increased at the lowest iron dose relative to untreated but remain stable at the higher doses. 
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Figure 2.1D C3 protein levels increase, relative to untreated, in the conditioned medium of cells 
treated with increasing doses of FAC for 2d. 
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resulted in further increases in C3 mRNA levels up to 20-fold (Fig. 2.1E).  Yet, it was determined 
that only treatment with FAC, but not other transition metals (Mn2+, Ni2+, and Cu2+), induced 
increases in C3 mRNA levels relative to untreated (Fig. 2.1F).  C3 mRNA up-regulation was also 
observed in cells treated with holo-transferrin (holo-Tf), the extracellular iron carrier protein.  The 
levels increased by ~2.5-fold (Fig. 2.1G), while TFRC mRNA levels decreased by ~40% (Fig. 
2.1H).  Overall, these data delineate a specific, iron-induced C3 gene response within the RPE 
cell. 
 
Pathway enrichment analysis implicates TGF-β signaling in iron-induced C3 expression 
To characterize the potential molecular pathway(s) affected by iron treatment and identify the 
one(s) responsible for C3 induction, we performed a whole genome microarray on untreated 
ARPE-19 cells and cells treated with 250 µM FAC for 48h/2d (Supplemental Table).  Iron loading 
resulted in 95 transcripts with up-regulated expression and 122 transcripts with down-regulated 
expression of magnitude ≥1.5-fold and q <10%.  After eliminating non-annotated entries, we 
derived a list of 70 up-regulated and 87 down-regulated transcripts (total 157), of which 9 up-
regulated ones and 7 down-regulated ones are of magnitude ≥2.0-fold (Table 2.4).  Both C3 and 
TFRC are among these “top hits” (Table 2.4), validating our results above in Fig. 2.1A and 2.1B. 
Using the list of 157 transcripts with expression change magnitude ≥1.5-fold as input into the 
program DAVID, we generated another list of “pathways” and “biological processes” that best 
represent these transcripts.  The entry “TGF-β signaling” topped this list, fitting within the 
constraint of false-discovery rate (Benjamini-Hochberg) <10%.  Subsequent entries do not meet 
this statistical significance cutoff. 
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Figure 2.1E C3 mRNA levels are increased relative to control cells at each of the 2d, 4d, and 8d 
time points after the initial 250µM FAC treatment. 
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Figure 2.1F C3 mRNA levels of cells treated with Fe3+, Mn2+, Ni2+, or Cu2+ at 250µM 
concentration for 2d, with only Fe3+/FAC showing an increase in C3 mRNA relative to untreated.  
Cell viabilities for cells treated with the other transition metals were similar to those for Fe3+. 
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Figure 2.1G and H C3 mRNA levels of cells treated with 9.75 mg/ml holo-Tf are increased 
relative to those of apo-Tf-treated cells, with a corresponding decrease in TFRC mRNA. 
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Table 2.4. The most up-regulated and down-regulated annotated transcripts in ARPE-19 cells treated with FAC 
Transcript ID RefSeq Gene name Gene symbol 
Fold change 
(log2)a 
Transcripts with up-regulated expression 
16955939 NM_015541 leucine-rich repeats and immunoglobulin-like domains 1 LRIG1 2.69089 
16911261 NM_001200 bone morphogenetic protein 2 BMP2 2.44466 
16996813 NM_005582 CD180 molecule CD180 2.30087 
17089003 NM_182487 olfactomedin-like 2A OLFML2A 2.24716 
16750996 NM_020039 amiloride-sensitive cation channel 2, neuronal ACCN2 2.18511 
16867784 NM_000064 complement component 3 C3 2.18391 
16829801 NM_001124758 spinster homolog 2 (Drosophila) SPNS2 2.18123 
17096285 NM_001333 cathepsin L2 CTSL2 2.16549 
16785938 NM_015351 tetratricopeptide repeat domain 9 TTC9 2.09855 
Transcripts with down-regulated expression 
17056984 NM_002192 inhibin, beta A INHBA -2.02469 
16907639 NR_036227 microRNA 2355 MIR2355 -2.07836 
16976599 NM_014465 sulfotransferase family, cytosolic, 1B, member 1 SULT1B1 -2.11595 
16912362 NM_181353 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein ID1 -2.96384 
16963241 NM_003234 transferrin receptor (p90, CD71) TFRC -3.07206 
16683377 NM_002167 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein ID3 -4.0267 
17084723 NM_001216 carbonic anhydrase IX CA9 -4.35892 
aData are relative to control, untreated cells. 
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Iron-induced C3 up-regulation is independent of TGF-β ligands 
To determine whether TGF-β ligands drive C3 up-regulation following iron treatment, we 
incubated ARPE-19 cells with human recombinant TGF-β1, TGF-β2, or TGF-β3.  By qRT-PCR 
analysis, TGF-β1 (Fig. 2.2A), and to a lesser degree TGF-β3 (data not shown) showed significant 
down-regulation of C3 mRNA levels, whereas TGF-β2 showed no significant difference when 
compared to untreated control (data not shown).  These results suggest that the ligands, via 
canonical TGF-β pathway activation, do not account for the increase in C3 mRNA levels 
observed with iron loading.  The significant up-regulation of specific downstream target genes of 
these ligands, such as PAI-1 in the case of TGF-β1 (Fig. 2.2A), demonstrated that the canonical 
TGF-β pathway is intact and that TGF-β receptor blockade using SB431542 is efficacious.  We 
then investigated the levels of TGFB1 mRNA and TGF-β1 protein under untreated and FAC-
treated conditions and found that mRNA levels were increased slightly by ~1.3-fold, but the 
secreted protein levels were moderately but significantly decreased, by ~20% (Fig. 2.2B).  This 
led to the hypothesis that basal TGF-β levels, though suppressed by FAC, are important for 
regulating C3 mRNA levels.  To test this hypothesis, we treated cells with anti-TGF-β1/2/3 
neutralizing antibody and found that C3 mRNA levels were increased by ~1.7-fold relative to 
control conditions and PAI-1 mRNA levels were decreased by ~60% in the same comparison 
(Fig. 2.2C).  We further asked whether basal TGF-β activity affects the degree of FAC-induced 
C3 up-regulation.  To determine this, we co-treated anti-TGF-β1/2/3 antibody and FAC, which 
showed no significant difference in C3 mRNA levels compared to FAC only (~2.5-fold over 
untreated) (Fig. 2.2D).  PAI-1 mRNA levels were repressed by FAC though not further lowered by 
neutralizing antibody (Fig. 2.2D). 
 
Iron-induced C3 up-regulation involves ERK1/2 and SMAD3 non-canonical TGF-β signaling 
Iron has been shown previously to induce ERK1/2 phosphorylation in rat hippocampal neurons 
and mouse neurosensory retina (Hadziahmetovic et al., 2011a; Muñoz et al., 2011).  To examine  
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Figure 2.2A C3 mRNA levels in ARPE-19 cells are repressed by exogenous TGF-β1 (10 ng/ml; 
2d) and this inhibition is partially relieved by TGF-β receptor inhibitor SB431542 (100 nM; 2d).  In 
contrast, PAI-1 mRNA levels are significantly increased by TGF-β1 and this increase is partially 
inhibited by SB431542. 
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Figure 2.2B TGFB1 mRNA levels show an increase with FAC treatment; TGF-β1 protein levels in 
the conditioned medium of FAC-treated cells show a significant decrease relative to untreated. 
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Figure 2.2C C3 mRNA levels are increased with addition of neutralizing antibody anti-TGF-β1/2/3 
(10µg/ml; 2d) when compared to control or IgG-treatment conditions.  PAI-1 mRNA levels are 
decreased in the same comparison. 
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Figure 2.2D C3 mRNA levels are not significantly changed with co-treatment of anti-TGF-β1/2/3 
antibody and FAC when compared to FAC only.  PAI-1 mRNA levels are decreased to similar 
levels with co-treatment of anti-TGF-β1/2/3 antibody and FAC compared to FAC only.   
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if ERK1/2 plays a role in iron induction of C3, we pre-treated ARPE-19 cells with PD98059, a 
pharmacologic inhibitor of MEK1/2, the kinase upstream of ERK1/2, followed by FAC treatment.  
This inhibitor was able to block FAC-induced C3 up-regulation (Fig. 2.3A).  Another inhibitor that 
functions by a similar mechanism, U0126, achieved the same effect (data not shown).  In 
contrast, inhibitors to the two other MAPK classes, SB202190 against p38 and SP600125 against 
JNK1/2/3, did not suppress FAC-induced C3 up-regulation (Fig. 2.3A).   
 
ERK1/2 can phosphorylate the linker region residues of SMAD2/3, central components in the 
TGF-β signaling pathway (Bae et al., 2012; Hough et al., 2012; Kamato et al., 2014; Matsuura et 
al., 2005; Wang et al., 2009).  In the present study, FAC did not induce linker region 
phosphorylation of SMAD2 (data not shown).  Thus, to assess whether SMAD3 plays a direct role 
in C3 induction, we co-administered a specific inhibitor of SMAD3 function, SIS3 (Jinnin et al., 
2006), with FAC, and found that this compound suppressed the up-regulation (Fig. 2.3B).  SIS3 
alone also decreased C3 mRNA levels relative to the untreated baseline (Fig. 2.3B), suggesting 
that the inhibitor modulates basal C3 expression. Furthermore, ARPE-19 cells co-treated with 
SIS3 or PD98059 and FAC showed diminished levels of C3 protein in the conditioned media 
compared to cells treated with FAC alone (Fig. 2.3C).  Expression of TGF-β1-responsive gene 
PAI-1 was inhibited by SIS3, but not by PD98059.  The FAC-induced repression of PAI-1 mRNA 
levels was relieved by PD98059 (Fig. 2.3D).  To determine the temporal sequence of ERK1/2 
phosphorylation and SMAD3 activity, we treated cells with FAC for different lengths of time (0, 1, 
3, 6h) in the absence and presence of SIS3 and found no difference in p-ERK1/2 levels by 
Western blotting at each of the time points examined (Fig. 2.3E).  In contrast, PD98059 inhibited 
FAC-induced SMAD3 linker phosphorylation at S213 (see below, Fig. 2.4C).  These findings 
place ERK1/2 upstream of SMAD3 in an FAC-induced signaling pathway. 
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Figure 2.3A C3 mRNA levels in ARPE-19 cells treated with MEK1/2 inhibitor PD98059 (5 µM; 
2d), p38 inhibitor SB202190 (20 µM; 2d), or JNK1/2/3 inhibitor SP600125 (50 µM; 2d) alone and 
plus FAC.  Control contains vehicle only (DMSO).  Relative to FAC alone, only PD98059 showed 
a significant decrease in C3 mRNA levels when co-treated with FAC. 
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Figure 2.3B The specific inhibitor of SMAD3, SIS3 (2 µM; 2d), inhibited FAC-induced C3 up-
regulation.  SIS3 decreased basal C3 mRNA levels. 
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Figure 2.3C Iron-induced increases in C3 protein levels in the conditioned media are diminished 
by SIS3 and PD98059. 
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Figure 2.3D SIS3 inhibited PAI-1 mRNA levels to the same extent as FAC, while PD98059 had 
no significant effect.  Co-treatment with SIS3 and FAC showed no additional suppression of PAI-1 
mRNA levels, but co-treatment with PD98059 and FAC restored them to baseline. 
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Figure 2.3E Western blot and densitometry analysis for p-ERK1/2 and ERK1/2 in lysates derived 
from cells at different time points (0, 1, 3, 6h) post-FAC treatment, with or without SIS3 co-
treatment.  SIS3 showed no effect on the FAC-induced increase of p-ERK1/2 at 1h. 
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Iron-induced changes in SMAD3 phosphorylation are distinct from canonical TGF-β effects 
Since C3 up-regulation involves SMAD3 activity, we probed the phosphorylation status of SMAD3 
following iron treatment. Using phospho-specific antibodies directed against a linker region 
residue (S213) and the C-terminal residues (S423/425), we found two directly opposite effects: p-
SMAD3 (S213), shown as a 150 kDa band, gradually increased at time points up to 48h/2d, while 
p-SMAD3 (S423/425) decreased in the same time course (Fig. 2.4A).  The p-SMAD3 (S213) 
antibody-detectable 52 kDa band remained at baseline levels. TFRC protein levels diminished as 
a reflection of increasing LIP (Fig. 2.4A).  To test the specificity of the anti-p-SMAD3 (S213) 
antibody in Western blotting (Fig. 2.4B), we transfected cells with a construct expressing FLAG-
SMAD3 and detected a band at 54 kDa.  We also transfected a construct expressing FLAG-
SMAD3 EPSM (with mutated linker region phosphorylation sites) and detected virtually no band.  
Finally, we transfected a construct expressing FLAG-SMAD3 EPSM A213S (with residue 213 
reverted back to Serine) and detected the band once again.  This, together with SMAD3 shRNA 
data to be shown below (Fig. 2.6A), suggest that the 150 kDa band detected in un-transfected 
cells contains p-SMAD3 (S213).  Western blots also showed that the SMAD3 inhibitor SIS3 and 
MEK1/2 inhibitor PD98059 can suppress iron-induced increases in p-SMAD3 (S213) levels, 
supporting further the model that ERK1/2 and SMAD3 are in the same signaling pathway (Fig. 
2.4C).  Of note, p-SMAD3 (S213) levels decreased with SIS3 treatment compared to the 
untreated baseline.  This finding correlates with decreased C3 mRNA levels observed in the 
same comparison in Fig. 2.3B.  In addition, SIS3 can suppress basal p-SMAD3 (S423/425) levels 
to the same extent as FAC alone while PD98059 showed no such effect on the phosphorylation 
of these C-terminal residues (Fig. 2.4C).   
 
To gain insight into the role of endogenous TGF-β on the regulation of p-SMAD3 (S213) and p-
SMAD3 (S423/425), we treated cells with BSA, IgG or anti-TGF-β1/2/3 antibody with or without 
FAC.  Anti-TGF-β1/2/3 antibody alone dramatically decreased basal, TGF-β-sustained p-SMAD3  
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Figure 2.4A Western blot and densitometry analysis of ARPE-19 cell lysates for p-SMAD3 (S213), p-SMAD3 (S423/425), SMAD3, and TFRC in a 
FAC treatment time course experiment.  The p-SMAD3 (S213) 150 kDa band increased while the p-SMAD3 (S423/425) and TFRC bands 
decreased in intensity in a time-dependent manner. The p-SMAD3 (S213) antibody-detectable 52 kDa band showed no significant change in the 
same time course. The SMAD3 protein levels also remain unchanged.
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Figure 2.4B Cells transfected with constructs expressing FLAG-tagged SMAD3, SMAD3 EPSM (linker mutations), and SMAD3 EPSM A213S 
(mutation reverted at residue 213) showed specificity of the antibody used to detect p-SMAD3 (S213) in Western blots.   
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Figure 2.4C Western blot and densitometry analysis of p-SMAD3 (S213) showed that co-treatment with SIS3 or PD98059 and FAC reduced the 
intensity of this band relative to FAC alone.  SIS3 decreased the basal p-SMAD3 (S213) levels.  Blot and analysis of p-SMAD3 (S423/425) 
demonstrated that SIS3 reduced band intensity to the same extent as FAC alone, while PD98059 had no significant effect.  Co-treatment with 
either inhibitor with FAC showed no significant difference with FAC alone. 
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 (S213) (Fig. 2.5A).  In the presence of this antibody, iron retained its ability, albeit less, to induce 
formation of the p-SMAD3 (S213) complex.  Anti-TGF-β1/2/3 antibody alone also decreased p-
SMAD3 (S423/425) levels, as expected, while iron treatment potentiated this suppressive effect.  
In contrast, cells treated with exogenous TGF-β1 for 1h demonstrated no significant difference in 
p-SMAD3 (S213) levels but up-regulated p-SMAD3 (S423/425), consistent with canonical 
signaling effects (Fig. 2.5B).  This increase returned to basal level at 2d (data not shown). 
 
To verify that the 150 kDa band does contain SMAD3 and more specifically, p-SMAD3 (S213), 
we transduced ARPE-19 cells with lentiviral constructs expressing shRNA to stably knockdown 
SMAD3 protein (Fig. 2.6A).  With SMAD3 knockdown (sh-SMAD3), the iron-induced increase in 
intensity of the 150 kDa band as detected by anti-p-SMAD3 (S213) is diminished, unlike in the 
control cell lines un-transduced, vector, and sh-null, which are shown in the same panel (Fig. 
2.6A).  In addition, qRT-PCR measurement of C3 mRNA levels in sh-SMAD3 cells revealed a 
lack of FAC-induced up-regulation, which was present in the three control cell lines (Fig. 2.6B).  
To determine whether the p-SMAD3 (S213)-containing protein complex (150 kDa) undergoes 
nuclear translocation, we performed cellular fractionation on un-transduced cells with or without 
FAC treatment.  This band, regardless of iron treatment, localized only to the non-nuclear 
fraction, suggesting that the complex does not translocate to the nucleus (Fig. 2.6C).  In addition, 
the p-SMAD3 (S213) antibody-detectable 52 kDa protein is not induced by FAC in either the non-
nuclear or the nuclear compartment (Fig. 2.6C). 
 
Iron-induced increases in CEBPD mRNA levels and C/EBP-δ protein levels in both the non-
nuclear and nuclear compartments are dependent on SMAD3 activity 
It has been reported that SMAD3 physically interacts with C/EBP-δ and inhibits the transcription 
of C/EBP target genes important for adipocyte differentiation (Choy and Derynck, 2003).  To  
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Figure 2.5A Western blot and densitometry analysis of p-SMAD3 (S213) and (S423/425) in cells treated with BSA, IgG, or anti-TGF-β1/2/3 
antibody in the presence or absence of FAC showed the combined effect of iron and neutralization of canonical TGF-β signaling.  SMAD3 protein 
levels increased after anti-TGF-β1/2/3 antibody treatment relative to control condition, BSA with no FAC.  Only the antibody plus FAC condition is 
statistically significant.
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Figure 2.5B Western blot and densitometry analysis following treatment with exogenous TGF-β1 
(10 ng/ml; 1h) showed no significant change in p-SMAD3 (S213) and increased p-SMAD3 
(S423/425). 
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Figure 2.6A Western blot and densitometry analysis for SMAD3, p-SMAD3 (S213), and TFRC of ARPE-19 cell lysates derived from un-
transduced (control), vector, sh-null, and sh-SMAD3 lines, each in the absence or presence of FAC.  Efficient knockdown of SMAD3 decreased 
the formation of p-SMAD3 (S213)-containing complexes at 150 kDa.
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Figure 2.6B The FAC-induced increase in C3 mRNA levels is observed in the un-transduced, 
vector, and sh-null cell lines but is absent in the sh-SMAD3 cell line. 
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Figure 2.6C Western blot for non-nuclear and nuclear lysates of untreated and FAC-treated cells.  
The p-SMAD3 (S213)-containing complex at 150 kDa localize only to the non-nuclear fractions.  
The p-SMAD3 (S213) antibody-detectable band at 52 kDa is essentially unchanged by FAC 
treatment in both the non-nuclear and nuclear fractions.   
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probe the regulatory relationship between iron, SMAD3, and C/EBP-δ, we measured CEBPD 
mRNA levels and found that FAC up-regulated CEBPD.  Co-treatment with SIS3 and FAC 
significantly decreased these levels (Fig. 2.7A).  This finding posits a crucial role for SMAD3 in 
FAC-induced CEBPD gene regulation.  In testing TGF-β-mediated basal CEBPD regulation, we 
found that anti-TGF-β1/2/3 antibody alone increased CEBPD mRNA levels by a modest ~1.3-fold 
relative to control (Fig. 2.7B).  FAC increased CEBPD mRNA levels by ~2-fold, with co-treatment 
of FAC and anti-TGF-β1/2/3 antibody not significantly different from FAC alone (Fig. 2.7C).   The 
trends in these neutralizing antibody experiments correlate with those found when measuring C3 
mRNA levels (Fig. 2C, 2D). 
 
FAC also increased non-nuclear and nuclear C/EBP-δ protein levels in a time-dependent manner 
(Fig. 2.7D).  Next, we aimed to understand SMAD3’s role in iron-induced C/EBP-δ nuclear 
accumulation by comparing nuclear C/EBP-δ levels in the absence or presence of FAC for the 
sh-SMAD3 and control cell lines.  We showed that SMAD3 knockdown blocked the iron-induced 
increase within the nuclear as well as the non-nuclear compartments (Fig. 2.7E).  Interestingly, 
knockdown of SMAD3 elevated basal C/EBP-δ protein levels in both compartments in the 
absence of iron stimulus.  In agreement with protein quantitation, CEBPD mRNA levels were 
increased in both the puromycin-selected (Fig. 2.7E) and unselected sh-SMAD3 cells relative to 
controls (data not shown).   Taken together, these results suggest that SMAD3 mediates FAC-
induced increases in both CEBPD mRNA and C/EBP-δ protein in the non-nuclear and nuclear 
compartments.  
 
Iron can effect transcriptional up-regulation of C3 via the bZIP1 domain of the C3 promoter 
It has been reported that C/EBP-δ binds to the bZIP1 domain of the C3 promoter following 
stimulation by IL-1 (Juan et al., 1993; Maranto et al., 2008; Wilson et al., 1990).  To determine if  
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Figure 2.7A CEBPD mRNA levels in ARPE-19 cells are decreased by co-treatment with SIS3 
and FAC compared to FAC alone, which is increased relative to control. 
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Figure 2.7B CEBPD mRNA levels are increased with addition of neutralizing antibody anti-TGF-
β1/2/3 (10µg/ml; 2d) when compared to control or IgG-treatment conditions. 
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Figure 2.7C CEBPD mRNA levels are elevated with FAC treatment, but not significantly changed 
with co-treatment of anti-TGF-β1/2/3 antibody and FAC. 
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Figure 2.7D Western blot and densitometry analysis for C/EBP-δ in non-nuclear and nuclear lysates of cells treated with FAC in a time course.  
C/EBP-δ protein levels in the non-nuclear fraction show a time-dependent increase.  Nuclear accumulation of C/EBP-δ occurs with the duration of 
FAC treatment.  
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Figure 2.7E Knockdown of SMAD3 in sh-SMAD3 cells impaired FAC-induced increases in 
nuclear C/EBP-δ when compared to sh-null and un-transduced cells.  Basal C/EBP-δ levels 
increased in the sh-SMAD3 cell line relative to the controls. 
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iron can similarly stimulate the C3 promoter, we generated a set of luciferase constructs 
harboring 4 overlapping but discretely sized C3 promoter fragments and transfected them into 
ARPE-19 cells (Fig. 2.8A).  Cells transfected with each of the four fragments, approximately 500 
bp, 1 kb, 1.5 kb, or 2.0 kb in length relative to the C3 transcription start site, responded to iron 
treatment with increased Firefly luciferase activity, while Renilla luciferase, serving as transfection 
control, showed no significant difference between with or without iron conditions (Fig. 2.8A).  In a 
follow-up luciferase assay, cells transfected with a vector harboring the wild-type proximal 500 bp 
promoter fragment were compared with cells transfected to contain the same fragment with either 
the bZIP1 or bZIP2 domain mutations described previously (Juan et al., 1993).  As shown, bZIP1, 
but not bZIP2, lost its iron-inducible luciferase activity (Fig. 2.8B).  Therefore, bZIP1, the putative 
C/EBP-δ binding site, is likely to be important for iron-mediated C3 transcriptional up-regulation.     
 
Iron-induced C3 protein activation and alternative complement pathway activation can be 
suppressed by pharmacologic inhibition of SMAD3 and ERK1/2 
To examine iron’s effect on C3 protein activation, we used ELISA to measure the levels of the 
cleavage byproduct of C3 activation, C3a, in ARPE-19 cell conditioned media.  There was an iron 
dose-dependent increase in C3a levels (Fig. 2.9A).  We also found a significant decrease in C3a 
levels when comparing cells that are co-treated with SIS3 or PD98059 inhibitor and FAC to cells 
treated with FAC alone (Fig. 2.9B).  Evidently, pharmacologic suppression of C3 mRNA (Fig. 
2.3A, 2.3B) and protein (Fig. 2.3C) levels also translated into decreased C3 protein activation.  
By approximation, iron induced a comparable 2-fold change in both C3 and C3a levels relative to 
untreated (Fig. 2.3C, 2.9B).  Analogously, co-treatment with SIS3 or PD98059 and FAC 
compared to FAC alone resulted in ~25% decrease in both C3 and C3a levels (Fig. 2.3C, 2.9B).  
In addition, co-treatment with both inhibitors and FAC achieved commensurate levels of C3a 
protein as co-treatment of a single inhibitor and FAC (Fig. 2.9B).  To study the alternative 
complement pathway activation status, we measured the levels of the Factor B activation product,  
66 
 
 
Figure 2.8A ARPE-19 cells transfected with luciferase vectors containing a set of nested but different-sized C3 promoter fragments, as 
schematically indicated, uniformly displayed responsiveness to FAC treatment.  The results were corrected for transfection efficiency as measured 
by Renilla luciferase activity, which was not significantly changed by FAC.
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Figure 2.8B Cells transfected with the smallest fragment (500 bp) containing a wild-type (WT) 
sequence, the same fragment with a mutant bZIP1 domain, or the same fragment with a mutant 
bZIP2 domain are treated with or without FAC.  The bZIP1 mutant suppressed baseline and FAC-
inducible luciferase activities. The results were corrected for transfection efficiency as measured 
by Renilla luciferase activity, which was not significantly changed by FAC. 
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Figure 2.9A ELISA of C3a from the conditioned media of untreated ARPE-19 cells and those 
treated with different doses of FAC for 2d.  Compared to either untreated or 25 µM FAC-treated 
cells, the 250 µM FAC-treated cells showed a significant increase in C3a production. 
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Figure 2.9B C3a production is significantly decreased by co-treatment with SIS3 or PD98059 and 
FAC compared to FAC alone at 4d; co-treatment with both inhibitors and FAC did not further 
reduce C3a levels compared to co-treatment with a single inhibitor and FAC. 
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Factor Ba, and determined that relative to untreated, FAC induced Factor Ba production.  This 
effect is inhibited by co-treatment with SIS3 or PD98059 inhibitor and FAC (Fig. 2.9C).  Although 
this finding points to a possible co-regulation of Factor B and C3 expression, it is not further 
explored herein. 
 
Chronic iron overload in the RPE is associated with increased C3 expression and 
activation, as demonstrated by localized C3d deposition in vivo 
Our group has published a case report of post-mortem retinal findings in a human patient with 
aceruloplasminemia showing iron overload in the RPE cells (Wolkow et al., 2011).  In the present 
study, we used paraffin-embedded sections containing RPE cells of the macular region, where 
iron deposition is the most concentrated, and detected stronger signals for C3d, a C3 activation 
fragment, than in the same region of an eye from an age-matched patient without retinal disease 
(Fig. 2.10A).  The fluorescence pattern is punctate and distributed throughout the cell, a pattern 
that is absent in the sections from the normal eye.  Further, a ferroxidase conditional knockout in 
the RPE serves as a good ocular disease model for the human disease aceruloplasminemia.  As 
such, these BCre+, Cp-/-, HephF/F mice have a mosaic pattern of gene ablation, with select RPE 
cells exhibiting iron overload detected by L-ferritin antibody staining.  Cells showing strong L-
ferritin signal are highly correlated with cells showing increased C3d deposition (Fig. 2.10B). 
 
Discussion 
 
Main findings 
The main findings of our study suggest a model, schematically diagrammed in Fig. 2.11, as 
follows: First, increased iron in RPE cells stimulates the phosphorylation of ERK1/2, followed by 
SMAD3 (S213) phosphorylation in a pathway leading to C3 up-regulation.  Second, iron induces  
71 
 
 
Figure 2.9C ELISA using the same comparison as in B showed that production of Factor Ba, a 
marker of alternative complement pathway activation, is decreased by co-treatment with SIS3 or 
PD98059 and FAC compared to FAC alone. 
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Figure 2.10A Paraffin-embedded sections of normal and aceruloplasminemia human macular retina, with retina pigment epithelium (RPE) and 
Bruch’s membrane (BrM) labeled, are stained with antibodies against C3d (red) and DAPI for nuclei (blue).  Scale bars are equivalent to 50 µm. 
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Figure 2.10B Representative images of RPE cells (arrow) and BrM (arrowhead) in OCT-embedded retina sections of 12-month old C3-/- and 
BCre+, Cp-/-, HephF/F mice.  Cells with increased L-ferritin levels (green, left panels) have an associated increase in C3d deposition (red, middle 
panels).  The merged images, demonstrating co-localization, are shown in the right panels.  Scale bars are equivalent to 50 µm. 
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Figure 2.11 The molecular mechanism of iron-induced RPE C3 production involves ERK1/2, 
SMAD3, and C/EBP-δ signaling.  Increased intracellular iron (Fe3+) in RPE cells from FAC 
treatment stimulates the phosphorylation of ERK1/2, followed by SMAD3 linker (S213) 
phosphorylation (orange up arrow), in a non-canonical TGF-β pathway leading to up-regulation of 
C3, the central molecule of the complement cascade (The FAC-induced pathway is delineated by 
orange arrows).  MEK1/2 inhibitor PD98059 and SMAD3 inhibitor SIS3 can block FAC-induced 
C3 up-regulation.  FAC also results in decreased phosphorylation of SMAD3 C-terminal residues 
(S423/425) at the SSVS motif (orange down arrow).  Through SMAD3, FAC increases CEBPD 
mRNA and C/EBP-δ protein levels, possibly by inducing CEBPD expression and relieving 
SMAD3-mediated inhibition at baseline (orange X over blue inhibitory line).  The p-SMAD3 (S213) 
complex remains extra-nuclear.  In addition, FAC promotes the nuclear accumulation of C/EBP-δ 
protein.  C/EBP-δ likely binds to the bZIP1 domain of the C3 promoter, inducing C3 expression.  
Once translated into protein, C3 is secreted and cleaved into C3a and C3b.  Concurrently, Factor 
D catalyzes the activation of Factor B to form Bb and the cleavage product Factor Ba.  Factors 
C3b and Bb together form the alternative pathway (AP) C3 convertase to amplify the activation of 
C3 by forming more C3b and C3a.   The iron-induced non-canonical TGF-β pathway (orange) 
may cross-talk with the basal, canonical TGF-β pathway (blue; see discussion), which is initiated 
by the binding of TGF-β ligand to the TGF-β Receptor complex (Type I and II) at the plasma 
membrane.  Endogenous TGF-β binding maintains the phosphorylation levels of SMAD3 at both 
S213 and S423/425, ultimately acting as a negative regulator of basal C3 expression.  
Stimulatory arrows and inhibitory lines represent a functional link between the subsequent 
entities, not necessarily a direct interaction.  
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increases in linker region phosphorylation, i.e. p-SMAD3 (S213), and decreases in C-terminal 
phosphorylation, i.e. p-SMAD3 (S423/425).  Together these changes represent the effects of 
cross-talk between an iron-induced non-canonical TGF-β pathway and an intrinsic, canonical 
TGF-β signaling pathway.  Third, SMAD3 mediates the iron-induced up-regulation and nuclear 
accumulation of C/EBP-δ, a transcriptional inducer of C3.  Fourth, the bZIP1 domain, previously 
identified as a C/EBP-δ-binding region within the C3 promoter, is responsive to iron stimulation.  
Fifth, activation of C3 protein and Factor B, an activator in the alternative pathway, are induced by 
increased iron.  Sixth, in vivo studies support the molecular association between RPE intracellular 
iron overload and increased deposition of activated C3 fragments. 
 
Discussion 
The mechanistic findings in the present study are relevant to AMD, as the disease is associated 
with elevated RPE iron levels (Hahn P et al., 2003).  The increased iron leads to oxidative stress 
by Fenton chemistry in RPE cells, likely overwhelming their anti-oxidant defenses.  As a general 
concept, oxidative stress is considered as an inciting factor of complement over-activation in the 
RPE (Handa, 2012; Kunchithapautham et al., 2014; Thurman et al., 2009).  To determine whether 
iron can up-regulate RPE complement immune-mediated defenses, we treated ARPE-19 cells 
with a standard range of FAC doses (Salvador and Oteiza, 2011) and measured C3 mRNA and 
protein levels.  C3 activation indicates a mobilized arm of innate immunity and a possible buildup 
of an adaptive immune response (Markiewski and Lambris, 2007; Morgan et al., 2005).  We have, 
for the first time, provided evidence that iron triggers the transcriptional up-regulation, protein 
secretion, and proteolytic activation of C3.  Several other transition metals did not lead to C3 up-
regulation in the same experimental model.  We have also identified components of the TGF-β 
signaling superfamily that mediate iron-induced C3 expression.  
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Exogenous TGF-β1 ligand stimulates the canonical pathway (Massague, 2012; Wang et al., 
2009), resulting in repression of C3 and induction of PAI-1 mRNA levels.  These findings 
demonstrate that in ARPE-19 cells the machinery of the canonical TGF-β pathway is intact.  
When endogenous TGF-β ligands are neutralized in the absence of FAC, the resultant up-
regulation of C3 and down-regulation of PAI-1 mRNA levels reveal the regulatory role of the 
canonical TGF-β pathway at baseline.  Since addition of anti-TGF-β1/2/3 antibody alone up-
regulated C3 expression, one could hypothesize that signaling events of the iron-induced non-
canonical TGF-β pathway could cross-talk with those of the canonical pathway, leading to 
inhibition of the latter’s inhibitory effect on C3 expression.  Consistent with this hypothesis, we 
found that iron treatment results in a modest but significant decrease in endogenous TGF-β1 
levels, thereby attenuating canonical signaling.  Apparently, iron-mediated effects on the non-
canonical and canonical TGF-β pathways act together to up-regulate C3.  We further explored 
the relative contributions of these two pathways to C3 up-regulation.  The up-regulation of C3 as 
an outcome of activated ERK1/2 and SMAD3 in non-canonical signaling is approximately 1.5-fold 
more robust than the effect of neutralizing endogenous TGF-β signaling (Fig. 2.2C, 2.2D).   
Furthermore, co-treatment with anti-TGF-β1/2/3 antibody and iron did not show any additive 
effect on C3 up-regulation when compared to iron alone.  Taken together, it is plausible that 
inhibition of the inhibitory canonical TGF-β signaling plays an adjunctive role in iron-induced C3 
up-regulation. 
 
In the context of iron stimulation, the regulatory cross-talk between these two pathways may be 
mediated, in part, by ERK1/2.  ERK1/2 is thought to have a pathogenic role in both atrophic and 
neovascular AMD because p-ERK1/2 is increased in human geographic atrophy retinas (Dridi et 
al., 2012) and RAS/ERK signaling is implicated in oxidative stress-mediated VEGF secretion by 
ARPE-19 cells (Kunchithapautham and Rohrer, 2011).  ERK1/2 has been shown previously to 
phosphorylate several SMAD3 linker region residues in a variety of cellular contexts (Kretzschmar 
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et al., 1999; Matsuura et al., 2005; Tarasewicz and Jeruss, 2012; Wang et al., 2009; Wang, 
Guannan, 2008).   In the present study, we observed that iron-induced activation of ERK1/2, but 
not p38 or JNK1/2/3, up-regulates C3 in a non-canonical TGF-β pathway. Further, the MEK1/2 
inhibitor PD98059 blocks iron-induced increases in p-SMAD3 (S213).  Taken together, this 
suggests that iron activates ERK1/2 to phosphorylate SMAD3 at S213, which likely contributes to 
C3 up-regulation.  Meanwhile, phosphorylation of C-terminal residues (S423/425) is not affected 
by ERK1/2 inhibition in the absence or presence of iron (Fig. 2.4C).  Although induction of the 
TGF-β1 target gene PAI-1 is SMAD3 C-terminal phosphorylation-dependent (Hua et al., 1998; Liu 
et al., 1997), phosphorylation of the linker region by activated ERK1/2 may be important for iron’s 
inhibitory effect on PAI-1 expression.  We have shown that inhibition of ERK1/2 activity restores 
iron-suppressed PAI-1 mRNA levels back to baseline (Fig. 2.3D).  This finding implies that 
phosphorylation of the SMAD3 linker region plays a regulatory role in canonical, C-terminal 
phosphorylation-dependent gene expression.  Nevertheless, iron appears to utilize spatially 
distinct SMAD3 phospho-isoforms as a platform to convey different signals to effector genes, as 
exemplified by the transcriptional up-regulation of C3 versus the down-regulation of PAI-1. 
   
In ARPE-19 cells, the 150 kDa band detected by p-SMAD3 (S213) antibody, and up-regulated by 
iron, contains SMAD3.  Results from antibody specificity tests, SIS3 inhibition, and targeted 
knockdown of SMAD3 support this finding.   Previously, it was determined that SMAD3-containing 
complexes are distributed over a wide range of molecular weights (Jayaraman and Massagué, 
2000), and 150 kDa is within this range.  However, this 150 kDa complex should have dissociated 
under SDS-PAGE conditions.  The lack of dissociation then raises the possibility that either the 
complex is extraordinarily stable or it represents a covalently modified form of SMAD3 that cannot 
be effectively disrupted by SDS.  In post-mortem human RPE/choroid tissues, the most significant 
band detected by the same antibody against p-SMAD3 (S213) was higher than 52 kDa 
(approximately 70 kDa; data not shown).  Taken together, these results suggest that the apparent 
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molecular weights of p-SMAD3 (S213)-containing species are context-dependent.  The 150 kDa, 
p-SMAD3 (S213)-containing species remains in the non-nuclear compartment after iron 
treatment.  Phosphorylation at S213 may affect SMAD3’s interaction with other signaling 
mediators, one of which could be transcription factor C/EBP-δ, to effect the latter’s nuclear 
accumulation.  SMAD3 has been shown to directly interact with C/EBP-δ in the context of 
adipocyte differentiation (Choy and Derynck, 2003), though the details of how p-SMAD3 (S213) in 
ARPE-19 cells may regulate this interaction remain unknown.   
 
C/EBP-δ acts as the major protein responsible for the acute-phase C3 gene expression by 
binding to the bZIP1 domain in the promoter sequence (Juan et al., 1993; Maranto et al., 2008; 
Wilson et al., 1990).  The bZIP1 domain is required for basal and cytokine-inducible C3 
expression. Similarly, we find this domain to be important for iron-induced C3 transcription in 
ARPE-19 cells.  Also, we showed that iron-induced C3 up-regulation is accompanied by 
increased CEBPD mRNA and C/EBP-δ protein levels.  SMAD3 activity appears to mediate these 
increases, since SIS3 blocks iron-induced increases in CEBPD mRNA, and there was no 
significant difference in nuclear C/EBP-δ levels between untreated and iron-treated sh-SMAD3 
cells.  It should be noted that C/EBP-δ protein levels are elevated in sh-SMAD3 cells compared to 
the control cell lines, suggesting that SMAD3 inhibits basal C/EBP-δ expression.  In other words, 
the observed iron-induced increases in C/EBP-δ levels may result, at least in part, from the relief 
of SMAD3 inhibition of basal C/EBP-δ expression.  This mechanistic model is consistent with that 
of vascular smooth muscle cells in an anti-inflammatory state, in which TGF-β1-stimulated 
SMAD3 represses C/EBP-δ expression (Feinberg et al., 2004).  In a further study of basal 
repression of CEBPD, neutralization of endogenous TGF-β ligands in the absence of FAC 
resulted in a modest up-regulation of CEBPD, which is comparable in magnitude to the iron-
induced up-regulation of CEBPD (Fig. 2.7B, 2.7C).  Thus, similar to the regulation of C3 mRNA 
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levels, CEBPD mRNA levels are likely induced by iron through a non-canonical TGF-β pathway 
and through the relief of SMAD3-mediated basal inhibition. 
 
In AMD pathogenesis, it is thought that over-activation of the complement cascade, especially in 
the alternative pathway, contributes to the chronic inflammatory state. Our findings support the 
concept of a locally produced complement-mediated disease process, as iron insult of the RPE 
cell results not only in increased C3 transcription, but also in protein secretion and 
activation.  With more activated C3 in the RPE milieu, the complement cascade is mobilized to 
initiate immune-mediated inflammation.  Within the cascade, formation of the alternative pathway 
C3 convertase requires Factor B and generates byproduct Factor Ba so that more C3 can be 
activated (Kolb et al., 1989; Sahu and Lambris, 2001).  Although C3 activation and its 
downstream effects on RPE pathology are complex, our findings of increased C3a and Factor Ba 
levels are still suggestive of C3 and alternative pathway activation, respectively.  Befitting this 
complexity, while pharmacologic blockade of ERK1/2 or SMAD3 incompletely suppressed iron-
induced C3a formation, blockade of both targets provided no synergistic suppression (Fig. 2.9B).  
This supports our model of ERK1/2 and SMAD3 functioning in a single iron-mediated pathway.  
The incomplete suppression of C3a by the inhibitors, singly or in combination, points to the likely 
involvement of other iron-induced factors or processes in C3 activation.  Additionally, we provide 
strong evidence that excess intra-RPE iron can lead to local complement dysregulation, as 
reflected by C3d accumulation, in the individual RPE cells of an aceruloplasminemia patient and 
an animal model of RPE-specific iron overload.  In AMD, localized complement production and 
activation within the RPE layer may be more active in individuals with disease-associated 
complement gene polymorphisms.  Since ERK1/2, SMAD3, C/EBP-δ, and endogenous TGF-β 
are now implicated in RPE iron-C3 dysregulation, these signaling molecules may serve as useful 
therapeutic targets for ameliorating RPE pathology in AMD.  
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CHAPTER 3 
Preamble 
In the previous chapter, we examined the mechanism(s) by which iron may lead to complement 
dysregulation in the RPE cell.  An important follow-up question is whether increase in iron 
systemically or locally contributes more to iron overload in the RPE.  To determine how the retina, 
and more specifically the RPE may be loaded with iron in the disease context of AMD, we 
performed studies detailed below.  The work in this Chapter, entitled “A high serum iron level 
causes more retinal iron accumulation despite an intact blood-retinal barrier,” has been published 
as a Short Communication article in a November 2014 issue of American Journal of Pathology 
with Liangliang Zhao and myself, Yafeng Li, as the co-first authors, respectively. 
 
Abstract 
The retina can be shielded by the blood-retinal barrier. Since photoreceptors are damaged by 
excess iron, it is important to understand whether the blood-retinal barrier protects against high 
serum iron levels.  Bone morphogenetic protein 6 (Bmp6) knockout mice have serum iron 
overload. Herein, we tested whether the previously documented retinal iron accumulation in 
Bmp6 KO mice might result from the high serum iron levels or, alternatively, low levels of retinal 
hepcidin, an iron regulatory hormone whose transcription can be upregulated by Bmp6.  Further, 
to determine whether increases in serum iron can elevate retinal iron levels, we injected iron 
intravenously into wild-type (WT) mice.  Retinas were analyzed by qPCR and 
immunofluorescence to assess the levels of iron-regulated genes/proteins and oxidative stress. 
Retinal hepcidin mRNA levels in Bmp6 KO retinas were the same as, or greater than, that of age-
matched WT retinas, indicating that Bmp6 KO does not cause retinal hepcidin deficiency. 
Changes in mRNA levels of L-ferritin and transferrin receptor indicated increased retinal iron in 
intravenous iron-injected WT mice. Oxidative stress markers were elevated in photoreceptors of 
mice receiving intravenous iron. These findings suggest that elevated serum iron levels can 
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overwhelm local retinal iron regulatory mechanisms.  
 
Introduction 
Iron is necessary for life, but in excess it can be toxic. Therefore, iron is tightly regulated. Many of 
the genes that regulate iron  on the systemic level are expressed in the retina and may play a role 
in local iron regulation (Gnana-Prakasam et al., 2010). We previously studied double knockout 
(DKO) mice deficient for the iron exporting ferroxidases ceruloplasmin (Cp) and hephaestin 
(Heph) (Song and Dunaief, 2013). These DKO mice have an age-dependent retinal iron 
accumulation and degeneration (Hadziahmetovic et al., 2008b; Hahn et al., 2004c). DKO mice 
have retinal iron overload despite systemic iron deficiency, so it is likely that the retina 
accumulates iron as a result of impaired retinal iron export. We also studied mice with systemic 
knockout of the iron-regulatory hormone hepcidin (Hamp). These mice also have age-dependent 
retinal iron accumulation with degeneration (Hadziahmetovic et al., 2011b). Bmp6 is known to 
upregulate Hamp in the liver and retina (Meynard et al., 2009), and  Bmp6 KO mice have retinal 
iron accumulation similar to Hamp KO mice (Hadziahmetovic et al., 2011c). Since Hamp and 
Bmp6 KO mice have elevated serum iron levels, it is unclear whether the retinal iron 
accumulation in these mice results from elevated serum iron caused by diminished liver Hamp 
production or from low retinal Hamp levels impairing local iron regulation in the retina. 
 
There are several routes for iron influx yet only one for cellular iron efflux (Donovan et al., 2000; 
Gunshin et al., 1997; Soe-Lin et al., 2009); the transmembrane protein ferroportin can export iron 
out of cells. Ferroportin can be regulated by Hamp, which triggers its internalization and 
degradation, leading to decreased export of cellular iron (Nemeth et al., 2004). Hamp expression 
in the liver is increased by iron overload, and, following secretion into the bloodstream, limits 
intestinal iron absorption, macrophage iron recycling and hepatocyte iron release. In comparison, 
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iron deficiency anemia and tissue hypoxia can inhibit Hamp expression to increase iron supply  
for the body (Liu et al., 2005; Pak et al., 2006; Ramos et al., 2011).  
 
Hamp is  expressed in many tissues, including the  retina within photoreceptors, Müller cells, and 
RPE (Gnana-Prakasam et al., 2008). Ferroportin, the target of Hamp, is localized to RPE, 
photoreceptor inner segments, the outer plexiform layers, and inner limiting membrane (Hahn et 
al., 2004b). Locally synthesized Hamp may regulate ferroportin in the NR. To determine whether 
retinal Hamp deficiency contributes to the retinal iron accumulation in Bmp6 KO mice, we 
compared Hamp mRNA in Bmp6 KO versus WT mice.  We also tested whether WT mice given 
intravenous (I.V.) injections of iron sucrose would develop retinal iron accumulation despite the 
presence of Hamp produced locally in the retina.  
 
Materials and methods 
Animals—Bmp6 KO mice on the CD1 background were generated as described previously 
(Solloway et al., 1998). Bmp6 knockout male mice aged 2.5, 3.5, 5 and 10 months and age 
matched wild-type (WT) male CD1 mice were used for experiments. Wild-type C57BL/6J mice at 
2.5 months were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The C57BL/6J 
mice were treated with or without 1.2mg iron-sucrose (Venofer, American Regent, Shirley, NY) in 
200ml 0.9% saline solution via tail vein injection 3 times (once per week) until time of sacrifice.  
Experimental procedures were performed in accordance with the Association for Research in 
Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmology and vision 
research. All protocols were approved by the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. The eyes were enucleated immediately after sacrifice and were fixed 
overnight in 4% paraformaldehyde for immunofluorescence. 
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Immunolabeling—Mouse globes fixed in 4% paraformaldehyde were rinsed in PBS and the 
eyecups were dissected. The eyecups were cryoprotected in 30% sucrose solution overnight then 
embedded in optimal cutting temperature compound (Tissue-Tek; Sakura Finetek, Torrance, CA) 
and slowly frozen in 2-methylbutane on dry ice. Immunofluorescence was performed on sections 
of 10 µm thickness, as described previously (Dunaief et al., 2002). Primary antibodies were rabbit 
anti-L-ferritin (E17) at 1:200 dilution (kind gift from Paolo Arosio, University of Brescia), rabbit 
anti-MDA at 1:100 dilution (Alpha Diagnostic, San Antonio, TX) and rabbit anti-HNE at 1:100 
dilution (Alpha Diagnostic, San Antonio, TX). Primary antibody was detected using fluorophore-
labeled secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). 
Control sections were treated identically, except that primary antibodies were omitted. Sections 
were analyzed by fluorescence microscopy with identical exposure parameters using a Nikon 
TE300 microscope equipped with ImagePro Plus version 6.1 (Media Cybernetics INC., Bethesda, 
MD) software.  
 
RPE Isolation—We used a recently developed method for the rapid isolation of RPE cells for 
RNA extraction and analysis.(Xin-Zhao Wang et al., 2012) This employs simultaneous RPE cell 
isolation and RNA stabilization. Briefly, eyes were enucleated and placed on an ice-cold PBS-
soaked sponge. The peri-ocular tissues were removed and the eye was opened posterior to the 
limbus using Vannas scissors, then the anterior segment and the retina were removed.  The 
resulting posterior eye cups were quickly dipped into a PBS-containing microcentrifuge tube to 
remove any loosely adherent debris. Afterwards, the eye cup was immediately transferred into a 
microcentrifuge tube containing 200 µl of ice-cold RNA-protect cell reagent (Qiagen, Cat. No. 
76526) with gentle manual tapping of the tube every 1-2 min to accelerate the release of the RPE 
cells. After 10 min, the eye cup was removed from the solution with forceps. RPE cells were then 
centrifuged (5 min at 2750 rpm). The RNA isolation was performed with an RNeasy plus micro kit 
(Qiagen, Cat. No. 74034) according to the manufacturer’s protocol. 
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Quantitative real-time PCR—Liver, NR and RPE samples obtained from Bmp6 KO and WT 
mice were analyzed using quantitative real-time PCR for gene expression, as described 
previously (Song et al., 2012b). RNA isolation was performed with the RNeasy mini kit (Qiagen, 
Cat. No. 74106) according to the manufacturer’s protocol. The RNA was quantified with a 
spectrophotometer and stored at -80°C. cDNA was synthesized using TaqMan reverse 
transcription reagents (Applied Biosystems, Cat. No. 808-0234) according to the manufacturer’s 
protocol. TaqMan gene expression assays were obtained from Applied Biosystems and used for 
PCR analysis. Probes included hepcidin antimicrobial peptide (Hepc1, Mm04231240_s1), 
transferrin receptor (Tfrc, Mm 00441941_m1), L-ferritin (Ftl1, Mm03030144_g1), Von Willebrand 
factor homolog (Vwf, Mm00550376_m1), retinal pigment epithelium 65 (Rpe65, 
Mm00504133_m1), Collagen, type VI, alpha 1 (Col6a1, Mm00487160_m1). Eukaryotic 18S rRNA 
(Hs99999901_s1) served as an internal control due to its constant expression level among the 
studied sample sets. Real-time TaqMan RT-PCR (Applied Biosystems, Foster City, CA) was 
performed on an ABI Prism 7500 detection system using the ΔΔCT method, which provided 
normalized expression values. The amount of target mRNA was compared among groups of 
interest. All reactions were performed in biological (three mice) and technical (three real-time 
PCR replicates per mouse) triplicates. 
 
Statistical Analysis—The mean and the standard error were calculated for each comparison 
group. Statistical analysis was performed using the Student's two group, two sided t-test. For 
multiple comparisons, we used one way ANOVA with post hoc pairwise comparisons using 
Bonferroni correction for multiple comparisons. P<0.05 was considered statistically significant. All 
statistical analysis was performed with GraphPad Prism version 5 (GraphPad Software, San 
Diego, CA).  
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Results 
Regulation of hepcidin in NR in response to iron status 
Expression of Hamp in the liver, a key regulator of systemic iron metabolism, can be up regulated 
by Bmp6.3 Consistent with a previous report (Meynard et al., 2009),  Hamp mRNA levels in the  
livers of male Bmp6 KO mice at several ages were diminished compared to WT males (Fig. 3.1A, 
B and C).  
Because the Bmp6 pathway can increase Hamp expression at the systemic level, to determine 
whether it can also regulate retinal Hamp, we measured Hamp mRNA levels in NR and RPE. 
First, to test the level of RPE RNA enrichment in isolated RPE cells, we measured mRNA levels 
of RPE65, an RPE-specific marker, which was almost 6-fold higher in purified RPE samples 
compared with the RPE/choroid samples. In addition, the vWF and Collagen VI mRNAs, which 
are expressed in choroid and sclera, were decreased significantly in purified RPE samples 
compared with the RPE/choroid samples (Fig. 3.1D, E and F). 
The Hamp mRNA levels in NR showed no significant difference between Bmp6 KO and WT mice 
at 2.5 months and 3.5 months, and increased in Bmp6 KO compared with WT mice aged from 5 
months to 10 months (Fig. 3.1G). The Tfrc mRNA levels in Bmp6 KO NR showed no significant 
difference at 2.5 months, were decreased at 3.5 months, unchanged at 5 months and decreased 
at 10 months (Fig. 3.1H) in Bmp6 KO mice compared with age and sex matched WT mice. 
Decreased Tfrc mRNA levels indicate elevated iron levels, since increased intracellular iron 
prevents IRP1 and 2 from stabilizing the Tfrc mRNA (Rouault, 2006). 
Hamp mRNA levels in RPE showed no significant differences between Bmp6 KO mice and WT 
mice at both 5 and 10 months (Fig. 3.1I, K). The Tfrc mRNA level in RPE showed a significant 
decrease in Bmp6 KO mice compared with WT mice (Fig. 3.1J, L).
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Figure 3.1 Quantitative PCR results in liver, neural retina (NR), RPE/choroid (CH), and isolated 
RPE of Bmp6 KO and WT mice. Bmp6 KO mice have lower Hamp mRNA levels in liver than age- 
and sex-matched WT controls at 2.5mo (A), 3.5mo (B) and 10mo (C) of age. Relative mRNA 
levels of RPE65 (D), vWF (E) and collagen VI (F) in RPE/CH versus isolated RPE. RPE samples 
had enriched RPE65, limited vWF and barely detectable Col6a1 mRNA compared to RPE/CH. 
Relative mRNA levels of Hamp (G, I, and K) and Tfrc (H, J, and L) in NR of Bmp6 KO and WT at 
different ages. G: Hamp mRNA levels in 2.5mo and 3.5mo Bmp6 KO were not different from 
those in WT controls. However, Hamp mRNA levels are significantly higher in 5mo and 10mo old 
Bmp6 KO compared to WT controls. H: Tfrc mRNA levels in Bmp6 KO NR show no significant 
difference at 2.5mo and 5mo, and was decreased at 3.5mo and 10mo compared with age and 
sex matched WT mice. I and K: Hamp mRNA levels in RPE show no significant difference 
between Bmp6 KO mice and WT mice at both 5mo and 10mo. J and L: However, Tfrc mRNA 
levels show a significant decrease in Bmp6 KO mice compared to WT controls at both 5mo and 
10mo (J and L). (Values shown are means of ΔΔCT ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. N=3 biological and technical replicates for all qPCR experiments)  
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Eyes from C57BL/6J mice treated with I.V. iron have increased ferritin-L, and oxidative 
stress markers 
The levels of the cytosolic iron storage protein ferritin are regulated by labile iron levels through 
iron regulatory proteins IRP1 and IRP2 (Rouault, 2006).  Accordingly, when labile iron levels rise,  
ferritin translation increases, leading to increasing levels of both L-ferritin and H-ferritin proteins 
(Muckenthaler et al., 2008). RPE cells showed L-ferritin immunoreactivity that was stronger in the 
mice treated with I.V. iron than age-matched controls (Fig. 3.2A, B, C, and D).  Iron 
accumulation-induced lipid peroxidation was assessed by immunofluorescent detection of 
malondialdehyde (MDA) and 4-hydroxy-nonenal (HNE). These are reactive intermediates in the 
formation of advanced lipoxidation end products (ALEs). Thus, they are frequently measured as 
indicators of lipid peroxidation and oxidative stress. We detected an increase of MDA and HNE in 
the inner segment and outer plexiform layers of mice that were injected with iron compared to the 
controls (Fig. 3.2E, F, G, and H); accompanying quantification is presented (Fig. 3.2I, J, K, and 
L). 
Hepcidin, L-ferritin and transferrin receptor mRNA levels in C57BL/6J mice treated with I.V. 
iron 
In C57BL/6J mice treated with three weekly I.V. iron sucrose injections, Hamp and L-ferritin 
mRNA levels were significantly higher in the liver compared to control mice (Fig. 3.3A, C), 
whereas Tfrc mRNA levels were unchanged (Fig. 3.3B). Hamp mRNA levels were not 
significantly different in NR and RPE of the mice treated with or without iron (Fig. 3.3D, G). Tfrc 
mRNA levels were significantly lower in NR of iron-treated mice compared to control mice (Fig. 
3.3E), whereas L-ferritin mRNA levels (a less sensitive measure of iron) were unchanged (Fig. 
3.3F). L-ferritin mRNA levels were significantly higher in the RPE of iron sucrose-injected mice 
compared with controls, and Tfrc mRNA levels were significantly lower (Fig. 3.3H, I).  
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Figure 3.2. Iron labeling in RPE of i.v. Venofer (iron sucrose)-injected C57BL/6J mice. Iron level 
as determined by immunolabeling for L-ferritin (red), are greater in the RPE of Venofer-injected 
mice (B) compared to controls (A). C and D show the high magnification (60x objective) of the 
RPE layer (arrows) in A and B, respectively. Oxidative stress levels determined by 
immunolabeling for MDA and HNE, are greater in inner segments (arrows) and the outer 
plexiform layer (arrowheads) with Venofer injection (F and H) compared to controls (E and G). I-
L: Pixel density quantification of MDA and HNE immunostaining in the inner segments and outer 
plexiform layer of three mice with Venofer injection or controls. GCL, ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer. The scale bar in A and B represents 100µm (A, B, 
E-H); 33. 3µm (C and D). Statistical analysis was performed using the Student's two group, two 
sided t-test. *P < 0.05, **P < 0.01.  
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Figure 3.3 Quantitative PCR results in liver, retina, and RPE of intravenous Venofer (iron 
sucrose)-injected C57BL/6J mice. Relative mRNA levels of Hamp, Tfrc and L ferritin (Ftl) in liver 
(A-C), NR (D-F) and RPE (G-I) of mice with or without Venofer injection. Hamp (A) and Ftl (C) 
mRNA levels in liver were significantly higher in mice with Venofer injection compared to the 
controls. B: Tfrc mRNA levels in liver of mice with or without Venofer injection were not 
different. Hamp (D) and Flt (F) mRNA levels in NR of mice with or without Venofer injection are 
not different. E: Tfrc mRNA levels were significantly lower in mice with Venofer injection 
compared to the controls.  G: Hamp mRNA levels in RPE of mice with or without Venofer 
injection were not different. H: Tfrc mRNA levels were significantly lower in RPE Venofer 
injected mice compared to the mice without Venofer injection. I: Ftl mRNA levels were 
significantly higher in the RPE of mice with Venofer injection compared to the controls. Values 
shown are means of ΔΔCT ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. N=3 
biological and technical replicates for all qPCR experiments. 
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Discussion 
Previous studies showed elevated serum and retinal iron levels in systemic Hamp and Bmp6 KO 
mice (Hadziahmetovic et al., 2011b, 2011c). To determine whether the retinal iron accumulation 
was due to loss of Bmp6-stimulated retinal production of Hamp, we measured Hamp mRNA in 
the NR and RPE by qPCR in Bmp6 KO mice. Our results indicate an important influence of 
systemic Hamp (and, consequently, serum iron) levels on retinal iron. In Bmp6 KO mice, liver but 
not retinal Hamp levels were diminished.  
Bmp6 can upregulate Hamp expression systemically, and we hypothesized that there was a 
similar local regulatory mechanism in the retina. Despite retinal expression of Bmp6 and its 
receptors, retinal Hamp expression was not diminished in Bmp6 KO mice; it increased 
significantly. These results provide evidence that basal retinal Hamp expression is independent of 
the Bmp6 pathway, though it is difficult to speculate precisely what that regulatory mechanism 
could be.  As the retina takes in more iron from the iron-rich blood in Bmp6 KO mice, this iron 
appears to upregulate Hamp expression. As a measure of retinal iron levels, Tfrc mRNA at 2.5 
months was similar between KO and WT. The Tfrc level was decreased at age 3.5 months, 
indicating elevated retinal iron levels.  At 5 months, Hamp expression in NR was increased in 
Bmp6 KO mice, possibly diminishing the iron influx, as the Tfrc levels were normal. However, at 
10 months, Hamp levels were still higher in Bmp6 KO than age-matched WT, but the Tfrc levels 
were lower in the KO suggesting that the increased Hamp levels were insufficient to prevent 
further iron influx. 
In the RPE, 5 and 10 month old Bmp6 KO mice had decreased Tfrc mRNA compared to age and 
sex matched WT mice. This reflects increased RPE iron caused by high systemic iron levels; a 
reduction in local retinal Hamp levels was not responsible, since there was no difference in RPE 
Hamp mRNA levels between Bmp6 KO mice and WT. 
To further assess the effects of elevated systemic iron levels on retinal iron, we injected mice with 
I.V. iron sucrose, which is used in patients to treat iron-deficiency anemia. Following three weekly 
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I.V. injections, we confirmed that liver Hamp mRNA levels increased, reflecting elevated 
hepatocyte iron levels. Tfrc levels did not change in the liver, suggesting that sub-populations of 
liver cells did not experience enough of an iron load to down-regulate Tfrc mRNA. In both the 
RPE and NR of iron sucrose treated mice, Tfrc mRNA decreased compared with the control. The 
L-ferritin mRNA levels increased in the RPE of iron sucrose injected mice.  These results show 
that in WT mice, high systemic iron levels caused increased iron levels in the RPE, and, to a 
lesser extent, NR (since only Tfrc mRNA but not the less sensitive measure L-ferritin mRNA 
changed in the NR). Therefore, Hamp produced locally in the retina is insufficient to prevent 
retinal iron uptake in the context of increased blood iron levels. While elevated iron levels in the 
liver are a strong stimulus for Hamp expression, following iron sucrose injection, Hamp mRNA 
levels in the NR were unaltered; the acute systemic iron challenge did not cause retinal Hamp up-
regulation. 
After I.V. iron injection, oxidative stress markers MDA and HNE increase in the photoreceptor 
inner segments. The RPE accumulates more iron more than the NR, but oxidative stress markers 
were not elevated in the RPE. It is likely that the RPE has a more robust anti-oxidant defense 
system than the photoreceptors, resulting in the appearance of spatial separation between foci of 
increased ferritin staining and foci of increased oxidative stress marker accumulation.  Currently, 
we do not have complement data to accompany these findings. 
These studies emphasize the importance of blood iron levels on retinal iron levels; elevated blood 
iron levels may cause increased retinal iron-induced oxidative stress levels. Elevated systemic 
iron levels, whether caused by genetics or diet, may increase the risk of age-related retinal 
disease, including age-related macular degeneration. In support of this possibility, people eating 
diets high in red meat, which causes high levels of iron absorption by the gut, have an increased 
risk of AMD (Chong et al., 2009).
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CHAPTER 4 
Brief summary of major findings 
The accumulation of iron in the human retina is associated with the development of AMD, a 
disease characterized by central vision loss in millions of elderly individuals.  In AMD, one site of 
major pathology is the retinal pigment epithelium (RPE) cell layer.  Increased iron in the RPE cell 
and other cell types has been shown previously by our group to lead to some pathological 
features of AMD.  In mouse models of systemic iron overload and of RPE-specific iron overload, 
both developed by our group, there are more deposits of complement component 3 (C3) protein 
fragments in the RPE.  C3 is a central molecule in the innate immune complement system, which 
in recent years has become a focus of genetic, biochemical, and functional studies in the context 
of AMD with the aim of revealing novel targets for therapy.   
As part of our effort to understand how iron may act as a driver for AMD development, we 
discovered that increased iron within RPE cells can trigger the transcription, and subsequently 
secretion and activation of C3 through modulation of the TGF-β pathway.  We detail several 
signaling intermediates, notably ERK1/2, SMAD3, and C/EBP-δ that mediate this effect.  
However, the iron-dependent signal that results in ERK1/2 phosphorylation has not been fully 
characterized.  In fact, an excess dose of free radical scavenger is unable to mitigate iron-
induced C3 up-regulation, though a supra-physiologic dose of peroxide, to the detriment of the 
cultured ARPE-19 cells, is able to induce C3 up-regulation.  In all, we have not examined in detail 
as to how the iron-sensing and/or oxidative stress pathways may contribute to iron-induced C3 
up-regulation.  Nevertheless, the above-mentioned signaling intermediates and endogenous 
TGF-β ligands may have the potential to become therapeutic targets for the prevention and/or 
treatment of some forms of AMD. 
In terms of the contribution of systemic iron versus dysregulation of local iron homeostasis to 
retinal iron accumulation, we found that high systemic iron levels, rather than a reduction in local 
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retinal Hamp levels, was chiefly responsible iron overload in the RPE cell in Bmp6 KO mice.  As 
such, there was no difference in RPE Hamp mRNA levels between Bmp6 KO mice and WT, 
indicating that in vivo, local retinal Hamp expression may be subject to other layers or types of 
regulation, not the Bmp6 axis as initially elucidated in hepatic cells/tissues. 
Future directions 
The iron-induced C3 pathway in an alternative cell line and in vivo 
In Chapter 2, we detailed a putative mechanism for iron-induced C3 up-regulation in the 
immortalized human RPE cell line, ARPE-19.  In order to determine if this pathway is more 
broadly applicable in other cell lines of epithelial origin, it is advisable to conduct a similar set of 
experiments, minimally encompassing the C3 gene expression and p-SMAD3 Western blot 
studies.  We will use other adherent, non-cancer cell-derived cell lines, such as the hepatic 
epithelial cell line THLE-2/3.  We have tried the hepatic adenocarcinoma cell line HepG2 cells 
and did not see a significant up-regulation of C3 despite much lowered TFRC mRNA levels with 
iron treatment (data not shown).  The reasons for this finding are likely many, including but not 
limited to insufficient expression of iron-C3 pathway components and the lack of iron-induced 
pathway induction due to other effects of cellular transformation. 
We acknowledge that one of the major shortcomings of our studies in Chapter 2 is the absence of 
substantial evidence for pathway activation in vivo.  Although we show in Fig. 2.10 the elucidation 
of the iron-C3 pathway, the work is done entirely in ARPE-19 cells.  Since our ARPE-19 cells 
experienced a sub-acute influx (2d to 4d) of iron, we attempted to generate a sub-acute in vivo 
model of RPE iron overload by performing FAC and sham injections intravitreally in WT C57BL/6 
mice.  At several time points following injection (i.e. 2d, 4d, 8d) using an approximate effective 
dose of 250 μM or lower (25 and 50 μM), C3 mRNA levels in isolated mouse RPE cells were 
highly inconsistent and variable, despite standardization of the technique.  Focal iron-induced 
injury to the RPE may not have been widespread enough to detect global changes when we 
isolated all RPE cells from the mouse eyes for analysis. 
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Our studies may be better suited in genetic models of iron overload, such as the Cp-/-HephSla 
mice.  However, this would not be the sub-acute iron influx model that we used in ARPE-19 cells 
and signaling changes may be different or difficult to capture using established antibody-based 
techniques.  Furthermore, using the genetic mouse model would certainly require substantial 
more effort on animal husbandry and waiting time.  At the current juncture, we don’t have a 
satisfactory model for studying sub-acute iron-induced complement dysregulation in vivo.  
CRISPR/Cas9 
One of the major questions that remain to be answered in Chapter 2 of this thesis is the 
molecular composition of the 150 kDa, p-SMAD3 (S213)-containing species.  Currently, our 
knowledge extends to the finding that C3 up-regulation is highly correlated with increased 
formation or production of this 150 kDa species.  Since this 150 kDa species is highly resistant to 
dissociation of SDS and reducing agents such as DTT and TCEP, the logical approach to 
determining the binding partners of SMAD3 in this protein species would be to perform immune-
precipitation, preferably with a tagged protein for enhanced antigen recognition and specificity.  
Overexpression of FLAG (DYKDDDDK)-SMAD3 prevented the time-dependent formation of the 
150 kDa protein species following FAC treatment.  We hypothesize that the FLAG tag, although 
only 8 aa in length, may have prevented the interaction of SMAD3 and molecule X in the 150 kDa 
protein species.  Furthermore, the intracellular stoichiometry of SMAD3 is perturbed substantially 
in the context of overexpression, which may have untoward effects on the iron-induced formation 
of the 150 kDa complex.   
In light of the experimental difficulties observed with using traditional cell and molecular biology 
approaches, we would like to, as an immediate next step, express SMAD3 at endogenous levels, 
though still with a small protein tag.  We propose using CRISPR-Cas9 technology to selectively 
knockin the FLAG tag at the SMAD3 locus, but with a small buffer, or linker region between the 
tag and the SMAD3 protein proper.  To enhance FLAG flexibility and minimize steric hindrance, 
we propose using a 4X Gly sequence as the linker.  To enhance the probability of success, that 
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is, formation of the 150 kDa protein species with iron treatment, the FLAG tag would be 
engineered at the N- and C-termini, separately, to determine which would least affect the 
formation of the 150 kDa species. 
We anticipate, but hope to minimize, the off-target effects of the Cas9 enzyme, which would result 
in engineering the FLAG tag at other loci.  We would determine site specificity by correlating 
FLAG and SMAD3 immunoblotting.  The main techniques and procedures used will be derived 
from the a classic introduction on genome engineering using the CRISPR-Cas9 system (Ran et 
al., 2013). 
Tail vein injection of venofer in WT and Cfh mutant mice 
Individuals who harbor the disease risk-conferring polymorphisms in complement-related genes 
may be more vulnerable to pathological progression in the context of iron insult.  We alluded to 
this hypothesis in Chapter 2.  As a continuation of efforts to further understand the effect of labile 
iron on complement gene regulation and protein activity, we are IV injecting iron supplement 
Venofer, a drug approved for human therapy, into both WT and Cfh knockin mice.  The Cfh 
mutant mice harbor a D1210C mutation and have an impaired ability to bind and inactivate C3b.  
These mice, therefore, have systemic over-activation of the alternative complement pathway, 
which presents as a potentially useful model for studying retinal pathology in the context of iron 
insult with Venofer treatment.  We look forward to determining if there is a pathological 
phenotype.  If so, this would support disease relevance of the mechanistic work we described in 
Chapter 2.   
Therapeutic implications of our findings 
The work described is basic science in nature but has potential to translate into a novel 
therapeutic approach to prevent or slow the progression of geographic atrophy (RPE cell 
degeneration) in the dry form of AMD.  To date, most of the high-profile anti-complement 
therapies for AMD target the activation of complement.  Understandably, activation of 
complement leads to cell damage and inflammation, which are hallmark features of AMD.  In this 
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effort, pharmaceutical companies such as Alexion has developed a neutralizing antibody against 
complement component 5 (anti-C5 Nab) and Roche/Genentech has, in clinical trials, a promising 
drug called lampalizumab, which is also a neutralizing antibody but directed against Factor D 
(anti-Factor D), an activator of the alternative complement pathway known to be highly associated 
with AMD.  On the other hand, our work delineates a mechanism of C3 expression, a process 
that must occur before activation.  The pathway involved, TGF-β signaling, is an important and 
well-studied one implicated in many disease processes such as chronic inflammation, cell fate, 
and malignancy.  Our rationale is to target complement dysregulation in the context of AMD 
further upstream, before protein activation in the complement cascade.  To our knowledge, there 
is currently no major drug in the pipeline for the treatment of dry AMD that targets complement 
gene expression.  The development of therapies targeting C3 expression may result in more 
effective therapies or in the least, provide an effective additional, or adjunctive therapy to existing 
regimens.  We envision that the eventual therapy to modulate TGF-β signaling in the diseased 
RPE would be in the form of small molecule delivery by sustained release in the ocular micro-
environment, protein-based therapy, antibody-based therapy, or gene therapy.  Small molecules 
may be pharmacologic inhibitors or miRNA’s that modulate the activity and/or expression of 
pathway signaling intermediates.  Ophthalmologists who specialize in the posterior segment of 
the eye could implant or inject drug-containing sustained delivery devices in proximity to the outer 
retina, near the RPE cell layer for patients who are either at risk for developing dry AMD due to 
their genetic risk profile (a service already available) or at risk for further progression of RPE 
atrophy and continued loss of central vision.
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